{"gene":"CCL7","run_date":"2026-06-09T22:57:17","timeline":{"discoveries":[{"year":1993,"finding":"CCL7 (MCP-3/NC28) was molecularly cloned and identified as a CC chemokine with chemotactic activity for monocytes but not neutrophils; unlike MCP-1, the secreted MCP-3 protein is N-glycosylated. Expression is induced by PMA in U937 cells and super-induced by cycloheximide, and co-regulated with MCP-1 by IFN-γ and IL-13 in PBMC.","method":"cDNA cloning, recombinant protein expression, chemotaxis assay, glycosylation analysis, Northern blot/mRNA regulation studies","journal":"European cytokine network","confidence":"High","confidence_rationale":"Tier 1 / Strong — original cloning paper with functional reconstitution (chemotaxis assay), biochemical characterization (glycosylation), and regulatory studies; foundational result replicated across subsequent literature","pmids":["8318676"],"is_preprint":false},{"year":1994,"finding":"Mouse MCP-3 was identified as the MARC/FIC protein; a cDNA library from LPS-stimulated WEHI-3 macrophages yielded a sequence identical to mouse MARC, establishing MARC/FIC as the murine orthologue of human CCL7.","method":"cDNA library screening with human MCP-3 probe, sequencing","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct cDNA cloning with sequence identity confirmation, single lab","pmids":["8002978"],"is_preprint":false},{"year":1995,"finding":"CCL7 (MCP-3) binds CCR1 (C-C CKR1) as a functional high-affinity receptor: recombinant CCR1-expressing 293 cells bound 125I-MCP-3, MCP-3 induced directional migration of CCR1/293 cells, and MCP-3, MIP-1α, and RANTES cross-competed for binding and cross-desensitized migration responses.","method":"Stable transfection of CCR1 cDNA in HEK293 cells, 125I-radioligand binding competition, in vitro chemotaxis assay, calcium flux/desensitization","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted receptor-ligand interaction in defined transfected cells with radioligand binding and functional migration assays","pmids":["7545673"],"is_preprint":false},{"year":1995,"finding":"CCL7 (MCP-3) binds monocytes with high affinity (Kd ~1–3 nM, ~10,000 sites/cell) and signals through multiple CC chemokine receptors shared with MIP-1α, RANTES, and MCP-1, but also through receptor sites unique to MCP-3 (including sites shared with MIP-1β); MCP-3 was the only CC chemokine that consistently chemoattracted neutrophils in this study, implying a unique receptor on neutrophils.","method":"125I-MCP-3 radioligand binding on primary monocytes and neutrophils, calcium flux cross-desensitization, in vitro chemotaxis","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (binding, calcium flux, chemotaxis) on primary cells; replicated by subsequent receptor-cloning studies","pmids":["7589134"],"is_preprint":false},{"year":1996,"finding":"Murine CCR2 (mCCR2) was cloned and shown to bind mouse FIC (mouse CCL7) with high affinity; 125I-JE (mMCP-1) binding to mCCR2-expressing HEK293 cells was competed by FIC but not by MIP-1α, C10, or N51/KC, establishing mCCR2 as a functional receptor for mouse CCL7.","method":"cDNA cloning, stable expression in HEK293 cells, 125I radioligand binding competition","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct receptor-ligand binding reconstituted in defined cell system with radioligand competition","pmids":["8662823"],"is_preprint":false},{"year":1996,"finding":"N-terminally truncated CCL7 analog MCP-3(10–76) acts as a multi-receptor antagonist: it binds CCL7, MCP-1, and RANTES binding sites on THP-1 monocytes with high affinity but lacks chemotactic activity, inhibiting responses to all three chemokines, demonstrating that the N-terminus of CCL7 is critical for receptor activation but not binding.","method":"Radioligand binding competition on THP-1 cells, in vitro chemotaxis, enzyme release assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — structure-activity mutagenesis (N-terminal truncation) combined with binding and functional assays","pmids":["8631850"],"is_preprint":false},{"year":1996,"finding":"CCL7 (MCP-4 comparison study) acts as a potent chemoattractant for monocytes and T lymphocytes via shared MCP-1/MCP-3/RANTES receptors, and for eosinophils via eotaxin-shared receptors, establishing CCL7's broad receptor promiscuity across leukocyte subsets.","method":"Radioligand binding cross-competition, chemotaxis assay, cross-desensitization on purified leukocyte populations","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional receptor profiling in context of MCP-4 characterization; CCL7 data are direct comparisons","pmids":["8642349"],"is_preprint":false},{"year":1997,"finding":"CCL7 (MCP-3/FIC) is expressed predominantly in airway epithelium after allergen challenge; pre-treatment with anti-MCP-3/FIC antibody significantly inhibited OVA-induced eosinophilia in bronchoalveolar lavage (46% eosinophils in control vs 8% with anti-CCL7), establishing a functional role for CCL7 in eosinophil recruitment in allergic airway inflammation.","method":"Mouse OVA sensitization/challenge model, immunocytochemistry for cellular source, RT-PCR, antibody neutralization in vivo, BAL differential cell counts","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — antibody neutralization in vivo with quantitative cellular readout; source localization by immunostaining; replicated by subsequent studies","pmids":["9144514"],"is_preprint":false},{"year":1999,"finding":"CCL7 (MCP-3) binds CCR5 with high affinity (IC50 ~2.14 nM competing 125I-MIP-1β) but acts as a natural antagonist: it binds CCR5 without inducing functional responses (calcium flux, chemotaxis), fails to cause CCR5 endocytosis, and inhibits CCR5 activation by MIP-1β. It was a weak inhibitor of HIV infection despite blocking gp120 binding.","method":"Radioligand (125I-MIP-1β) competition binding on CCR5-stable transfectants, calcium flux assay, chemotaxis assay, receptor internalization assay, HIV infection inhibition assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal assays (binding, calcium, chemotaxis, internalization, HIV infection) in defined transfected cell system, single lab with rigorous controls","pmids":["10477718"],"is_preprint":false},{"year":2002,"finding":"CCL7 orchestrates oxidative stress-induced neutrophilic airway inflammation: ozone exposure up-regulated CCL7 protein in lung with airway epithelium as primary source; anti-CCL7 antibody decreased neutrophil recruitment by 63%, establishing a non-redundant role for CCL7 in neutrophil (not only monocyte) recruitment in vivo.","method":"Mouse ozone-exposure model, lung mRNA/protein quantification by RT-PCR/ELISA, IHC for cellular source, in vivo antibody neutralization, BAL differential cell counting","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo antibody neutralization with quantitative cellular phenotype; source identified by IHC; replicated in subsequent lung inflammation studies","pmids":["11777981"],"is_preprint":false},{"year":2002,"finding":"CCL7 (MCP-3) contributes 40–50% of eosinophil recruitment in type-2 (Th2-mediated, schistosomal antigen) pulmonary granulomas; endothelial cells in and near granulomas are a major in situ source of CCL7, and IL-4 drives maximal CCL7 expression from cultured mouse lung endothelial cells.","method":"Mouse pulmonary granuloma model, in vivo antibody neutralization, immunohistochemistry for source, IL-4 neutralization, cultured endothelial cell MCP-3 production assay","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo neutralization with quantitative eosinophil readout, source identified by IHC, mechanism (IL-4 regulation) confirmed in vitro","pmids":["12107110"],"is_preprint":false},{"year":2008,"finding":"CCL7 and MCP-1 (CCL2) provide additive, parallel contributions to CCR2-mediated Ly6C(high) inflammatory monocyte recruitment from bone marrow during Listeria monocytogenes infection; MCP-3−/− mice had fewer splenic and circulating Ly6C(high) monocytes, increased bone marrow monocytes, and fewer Tip-DCs, paralleling MCP-1−/− phenotype but not fully recapitulated by either single knockout.","method":"CCL7 knockout mice, L. monocytogenes infection model, flow cytometry for monocyte subsets, intracellular cytokine staining for Tip-DCs, bacterial burden quantification","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO model with defined cellular and in vivo phenotype, multiple outcome measures, comparison with CCL2-KO and CCR2-KO","pmids":["18453605"],"is_preprint":false},{"year":2008,"finding":"CCL7 and CCL2 selectively promote differentiation of Nurr1+ precursors into midbrain dopamine neurons and enhance neuritogenesis, acting via CCR1 and CCR2 expressed in the ventral midbrain; CCL7 expression is developmentally regulated and reduced in Nurr1 knockout mice.","method":"Primary ventral midbrain precursor cultures, CCL2/CCL7 treatment, immunofluorescence for TH+ neurons, Nurr1-KO mouse analysis, developmental mRNA expression analysis","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined in vitro differentiation assay, genetic model (Nurr1-KO), single lab","pmids":["18420193"],"is_preprint":false},{"year":2008,"finding":"CCL7 (MCP-3) promotes type I collagen secretion by fibroblasts through activation of TGFβ signaling/MAPK pathways; TGFβ1 in turn stimulates CCL7 gene expression in fibroblasts, creating a positive feedback loop; microarray analysis confirmed additive effects on key TGFβ-regulated transcripts (PAI-1, OSF2, IGFBP6).","method":"Recombinant MCP-3 treatment of fibroblasts, collagen secretion assay, MAPK pathway inhibitor experiments, TGFβ signaling analysis (Smad phosphorylation), microarray, qRT-PCR","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pathway analyses in fibroblast cultures with functional collagen readout, single lab","pmids":["19038247"],"is_preprint":false},{"year":2009,"finding":"IL-1β and TNF-α stimulate CCL7 protein production in rat astrocytes through NFκB and p38/JNK MAPK pathways (but not ERK); selective inhibitors of NFκB (MG-132, SC-514) and p38/JNK (SB203580, SP600125) blocked cytokine-induced CCL7 upregulation, establishing signaling pathways for astrocytic CCL7 induction.","method":"Primary rat astrocyte cultures, ELISA for CCL7/CCL2, selective pharmacological inhibitors of NFκB (MG-132, SC-514) and MAPK pathways","journal":"Brain research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway dissection with multiple inhibitors and quantitative protein output, single lab","pmids":["19577550"],"is_preprint":false},{"year":2009,"finding":"CCL7 and CCL2 together regulate the CCR2 pathway to limit IL-4 generation and control host resistance to Histoplasma capsulatum: CCL7 neutralization in CCL2−/− mice (but not wild-type) resulted in increased IL-4 production and elevated fungal burden, demonstrating functional redundancy between CCL7 and CCL2 via CCR2 in suppressing Th2 responses.","method":"CCL2-KO mice, CCR2-KO mice, in vivo CCL7 antibody neutralization, IL-4 ELISA/intracellular staining, arginase/YM1 transcription analysis, fungal burden quantification","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic and antibody neutralization approaches combined, defined mechanistic outcome (IL-4 regulation via CCR2), multiple orthogonal readouts","pmids":["19587014"],"is_preprint":false},{"year":2010,"finding":"CCL7 is markedly upregulated in carcinoma-associated fibroblasts (CAFs) co-cultured with oral squamous cell carcinoma (OSCC) cells; recombinant CCL7 promoted OSCC invasion and migration, and this was inhibited by CCL7 neutralizing antibody or anti-CCR1/anti-CCR3 antibodies, establishing CCL7-CCR1/CCR3 signaling as the axis for CAF-mediated cancer invasion.","method":"Microarray of co-culture vs monoculture, qRT-PCR, ELISA, invasion/migration assays, neutralizing antibody treatments, RT-PCR for receptor expression on cancer cells","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional neutralization experiments with specific readout, receptor identification by RT-PCR, single lab","pmids":["19937793"],"is_preprint":false},{"year":2012,"finding":"TLR9 signaling promotes early induction of CCL7 (but not CCL2) in the lung during Cryptococcus neoformans infection; CCL7 reconstitution in TLR9-deficient mice restored CD11b+ dendritic cell accumulation, IFN-γ production, and effector cell recruitment, placing CCL7 downstream of TLR9 in the afferent phase of antifungal immunity.","method":"TLR9-KO mice, C. neoformans lung infection, CCL7 reconstitution by intratracheal administration, flow cytometry for immune cell subsets, cytokine ELISA, fungal burden","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (TLR9-KO) combined with cytokine reconstitution, multiple cellular and molecular readouts","pmids":["22422883"],"is_preprint":false},{"year":2014,"finding":"CCL7 has multiple glycosaminoglycan (GAG)-binding epitopes distributed across its surface (identified by hydroxyl radical footprinting and mutagenesis), enabling it to bind heparan sulfate with high affinity (~equivalent to CCL2) as a functional monomer without oligomerization; this is distinct from CCL2, which requires oligomerization for full GAG binding affinity.","method":"Hydroxyl radical footprinting (mass spectrometry), site-directed mutagenesis, surface plasmon resonance with heparan sulfate","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal structural and biophysical methods (footprinting, mutagenesis, SPR) in a single rigorous study","pmids":["24727473"],"is_preprint":false},{"year":2014,"finding":"Let-7d directly targets the 3'UTR of CCL7 mRNA; let-7d overexpression in renal cell carcinoma cells reduced CCL7 protein, suppressed PBMC recruitment in vitro and tumor macrophage infiltration in vivo; exogenous CCL7 reversed let-7d-mediated inhibition of migration and PBMC recruitment, establishing CCL7 as a direct target of let-7d regulation.","method":"Luciferase 3'UTR reporter assay for let-7d targeting, qRT-PCR, cell migration/PBMC recruitment assays, xenograft mouse models, rescue experiments with exogenous CCL7","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct 3'UTR targeting confirmed by luciferase assay, functional rescue experiments, in vivo xenograft model, single lab","pmids":["25193015"],"is_preprint":false},{"year":2015,"finding":"CCL7 in rhinovirus 1B infection drives neutrophil and macrophage influx into lungs and activates NF-κB p65/p50 subunits and airway hyperreactivity; CCL7 neutralization reduced NF-κB activation and airway hyperreactivity in non-allergic mice, linking CCL7 to NF-κB-mediated inflammation downstream of rhinovirus infection.","method":"In vivo murine RV1B infection, anti-CCL7 antibody neutralization, NF-κB subunit activation assay, lung function measurement (airway hyperreactivity), flow cytometry for leukocyte influx","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo neutralization with NF-κB pathway readout, single lab, multiple outcome measures","pmids":["25847975"],"is_preprint":false},{"year":2016,"finding":"CCL7 signals through CCR3 on colon cancer cells to promote EMT, cellular proliferation, invasion, and migration via ERK and JNK signaling pathways; CCL7-overexpressing HCT116/HT29 cells showed enhanced liver and lung metastasis in orthotopic mouse models.","method":"CCL7 overexpression in colon cancer cell lines, in vitro invasion/migration/proliferation assays, ERK/JNK pathway inhibitor experiments, ectopic and orthotopic mouse xenograft models","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo functional studies with pathway inhibitors, single lab","pmids":["27167205"],"is_preprint":false},{"year":2019,"finding":"Intrathecal injection of CCL7 induced dose-dependent pain-related behavior in naive mice; intrathecal neutralizing anti-CCL7 antibody attenuated CCI-induced neuropathic pain and augmented morphine/buprenorphine analgesia; spinal CCL7 is produced by both microglia and astrocytes after sciatic nerve injury, placing CCL7 in the spinal nociceptive signaling axis.","method":"Chronic constriction injury (CCI) mouse model, intrathecal CCL7 injection (dose-response), intrathecal anti-CCL7 antibody, von Frey and cold plate pain tests, qRT-PCR for CCL7 in spinal cord, primary glial cell cultures","journal":"Cytokine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo gain- and loss-of-function with behavioral readout, cellular source identified in vitro, single lab","pmids":["31003094"],"is_preprint":false},{"year":2019,"finding":"CCL7 directly antagonizes neutrophil migration in vitro and negatively regulates neutrophil recruitment in Leishmania major-infected skin in vivo; CCL7-deficient mice showed enhanced neutrophilic infiltration with elevated IL-17 gene profile, and CCL7 add-back specifically reduced neutrophil influx, revealing a non-redundant role for CCL7 in limiting neutrophilic inflammation.","method":"CCL7-KO mice, L. major infection model, in vitro neutrophil migration assay with CCL7, in vivo CCL7 reconstitution, flow cytometry, cytokine profiling, parasite burden","journal":"Frontiers in immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with in vivo reconstitution and in vitro direct assay; multiple orthogonal readouts; clear mechanistic conclusion","pmids":["30671055"],"is_preprint":false},{"year":2019,"finding":"Irisin promotes C2C12 myoblast proliferation through ERK phosphorylation–dependent upregulation of CCL7; CCL7 knockdown suppressed irisin-induced proliferation, placing CCL7 as a downstream effector of irisin-ERK signaling in myoblast proliferation.","method":"Irisin treatment of C2C12 cells, ERK inhibitor (U0126), transcriptomic analysis, qRT-PCR, CCL7 siRNA knockdown, proliferation assays (Pcna, Mki67, Mcm2)","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown establishes functional requirement, pathway inhibitor confirms ERK dependency, single lab","pmids":["31518371"],"is_preprint":false},{"year":2020,"finding":"CCL7 recruits conventional DC1 (cDC1) into the lung tumor microenvironment to promote CD8+ and CD4+ T cell expansion; CCL7-deficient KP mice showed impaired cDC1 infiltration and T cell expansion, and CCL7 administration alone or with anti-PD-1 inhibited tumor development, establishing CCL7 as a cDC1-recruiting chemokine that enhances checkpoint immunotherapy.","method":"CCL7-KO in KrasLSL-G12D/Tp53fl/fl (KP) and KrasLSL-G12D/Lkb1fl/fl (KL) mouse models, flow cytometry, intratracheal CCL7 administration, anti-PD-1 combination therapy, survival analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO and reconstitution in syngeneic in vivo model, multiple cellular readouts, replicated across two NSCLC models","pmids":["33257678"],"is_preprint":false},{"year":2020,"finding":"B lymphocytes (particularly B220low innate B cells) produce CCL7 to recruit neutrophils and monocytes to the injured kidney; CCL7 blockade in mice reduced myeloid cell infiltration and ameliorated acute kidney injury, establishing B cell-derived CCL7 as a driver of sterile innate inflammation in AKI.","method":"Mouse AKI model, flow cytometry for B cell subsets and myeloid cells, B cell CCL7 production measurement, Siglec-G-deficient mice (increased innate B cells), in vivo CCL7 antibody blockade, human AKI patient cohort urinary CCL7 levels","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic model (Siglec-G-KO), antibody blockade with cellular quantification, multiple mouse and human cohorts","pmids":["32737150"],"is_preprint":false},{"year":2020,"finding":"SOX18 directly transactivates CCL7 promoter; CCL7 and CCR1 form a positive feedback loop (CCL7-CCR1-ERK/ELK1-SOX18) promoting gastric cancer invasion and metastasis; CCL7/MCAM knockdown reduced SOX18-mediated invasion, and CCR1 inhibitor BX471 suppressed SOX18-mediated metastasis.","method":"ChIP assay, luciferase reporter, CCL7/MCAM knockdown and overexpression, invasion/migration assays, ERK/ELK1 pathway inhibition, in vivo mouse metastasis models, BX471 (CCR1 inhibitor) treatment","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct transcriptional activation confirmed, functional rescue/knockdown experiments, defined signaling axis, single lab","pmids":["32616889"],"is_preprint":false},{"year":2020,"finding":"CCL7 and CCL2 redundantly mediate migration of CCR2+/CX3CR1+ immunosuppressive M-MDSCs into the glioblastoma tumor microenvironment via CCR2; combined neutralization of CCL2 and CCL7 completely blocked CCR2-expressing cell migration to glioma-conditioned media, while single knockdown of either was insufficient.","method":"Bone marrow-derived MDSC migration assays with recombinant CCL2/CCL7, KR158B glioma CCL2/CCL7 knockdown, CCL2+CCL7 combined neutralization antibody, flow cytometry for tumor-infiltrating MDSCs in vivo","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo combination neutralization establishes redundancy, multiple cell and molecular readouts, single lab","pmids":["36685592"],"is_preprint":false},{"year":2021,"finding":"BRG1 (a chromatin remodeling protein) interacts with AP-1 to drive CCL7 transcription in hepatocytes in a redox-sensitive manner; BRG1 hepatocyte-specific deletion abolished CCL7 induction and macrophage infiltration in liver injury models; CK2-catalyzed phosphorylation of BRG1 mediates this regulation, and the process is blocked by the antioxidant N-acetylcysteine.","method":"Hepatocyte-specific BRG1 conditional KO mice, LPS/MCD diet liver injury models, in vitro LPS/palmitate treatment of hepatocytes, Co-IP (BRG1-AP-1 interaction), pharmacological inhibition (N-acetylcysteine), ChIP, macrophage migration assay","journal":"Redox biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO in vivo, Co-IP for protein interaction, ChIP for chromatin regulation, pharmacological inhibition, multiple orthogonal methods","pmids":["34454163"],"is_preprint":false},{"year":2021,"finding":"CCL7 promotes M1 macrophage polarization via CCR1/JAK2/STAT1 signaling; in vivo CCL7-neutralizing antibody reduced macrophage infiltration and attenuated angiotensin II-induced abdominal aortic aneurysm; JAK2/STAT1 inhibition blocked CCL7-induced M1 activation in macrophages.","method":"Ang II mouse AAA model, ex vivo macrophage polarization assays, CCR1 blockade, JAK2/STAT1 inhibitor, in vivo CCL7-neutralizing antibody treatment, histology/immunostaining","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo neutralization and in vitro pathway inhibition, multiple readouts, single lab","pmids":["34189838"],"is_preprint":false},{"year":2021,"finding":"Astrocyte-derived CCL7 promotes microglial activation and pro-inflammatory cytokine release after traumatic brain injury; CCL7 knockout improved microglia-controlled inflammation and neurological outcomes; CCL7-siRNA attenuated LPS-induced pro-inflammatory markers in astrocyte-microglia co-cultures.","method":"Rat TBI model, CCL7-KO, in vitro LPS-stimulated astrocyte-microglia co-cultures with CCL7-siRNA, cytokine/marker quantification, neurological scoring","journal":"International immunopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo KO with behavioral and molecular readouts, in vitro siRNA confirmation, single lab","pmids":["34293712"],"is_preprint":false},{"year":2024,"finding":"CCL7 impairs endothelial function through CCR3 via downregulation of AKT-eNOS and AKT/NRF2/HO-1/VEGF/SDF-1 pathways and upregulation of ERK/NF-κB/IL-1β/IL-6/TNF-α pathways; CCL7 is induced in endothelial cells by high glucose through c-Fos/c-Jun signaling; endothelial cell-specific Ccl7 knockout in STZ-diabetic mice ameliorated vasculopathy, neovasculogenesis, and wound repair.","method":"CCL7 KD/neutralization in endothelial cells, recombinant CCL7 treatment, specific pathway inhibitors (AKT, ERK, NF-κB), Ccl7 global KO and endothelial cell-specific KO mice in STZ/db/db/HFD DM models, tube formation/migration assays, in vivo ischemia/wound models, flow cytometry for circulating EPCs","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models (global KO, EC-specific KO, antibody neutralization), multiple in vitro and in vivo readouts with defined signaling pathways, replicated across multiple DM models","pmids":["39231238"],"is_preprint":false},{"year":2025,"finding":"Endothelial cell-derived CCL7 signals via CCR1 on macrophages to upregulate KAT2A expression, which catalyzes STAT1 succinylation; this epigenetic modification increases STAT1 binding to glycolytic gene promoters, driving metabolic reprogramming (enhanced glycolysis) and M1 polarization in macrophages, promoting septic acute lung injury; Ccr1-KO mice showed attenuated lung inflammation.","method":"EC-specific CCL7 inhibition in sepsis model, CCR1-KO mice, KAT2A expression analysis, STAT1 succinylation assay, ChIP for STAT1 binding to glycolytic gene promoters, metabolic flux assay, macrophage polarization assay","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined epigenetic mechanism (succinylation) with ChIP, genetic KO model, functional macrophage polarization readout; single lab, abstract-level detail","pmids":["40755420"],"is_preprint":false},{"year":2020,"finding":"CCL7 secreted by Mo-MDSCs binds CCR2 on colorectal cancer micro-metastatic cells and activates JAK/STAT3 pathway to break dormancy and promote metastatic outgrowth; Co-immunoprecipitation confirmed CCL7-CCR2 co-localization; CCL7 inhibition maintained CRC cells in dormancy and reduced metastasis.","method":"Co-immunoprecipitation (CCL7-CCR2 interaction), in vitro dormancy cell models, mouse liver metastasis models, flow cytometry for MDSCs, qRT-PCR/Western blot for JAK/STAT3, in vivo CCL7/MDSC inhibitor administration","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP for protein interaction, in vivo dormancy model, JAK/STAT3 pathway validated, single lab","pmids":["33986252"],"is_preprint":false},{"year":2020,"finding":"CCL7 regulates invadopodia maturation by promoting MMP-9 targeting to the invadopodia complex via RhoA signaling; dominant-negative RhoA blocked CCL7/CCR3-induced invadopodia maturation and collagen degradation, while constitutively active RhoA rescued maturation in CCL7-silenced cells; ERK and PI3K pathways regulated the initiation (not maturation) stage.","method":"CCL7 siRNA in cancer cells, dominant-negative and constitutively active RhoA overexpression, MMP-9 localization by immunofluorescence, invadopodia/collagen degradation assay, ERK/PI3K inhibitors, in vivo metastasis assay","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic rescue experiments with dominant-negative/constitutively active GTPase, functional invadopodia assay, in vivo validation, single lab","pmids":["32217106"],"is_preprint":false},{"year":2022,"finding":"MSC-secreted CCL7 activates CCR1 on colorectal cancer cells, which downstream activates CBP/P300 to acetylate KLF5, promoting CXCL5 transcription; TGF-β (also secreted by MSCs) inhibits this process by regulating SMAD4 to suppress KLF5 transcriptional activation.","method":"Co-culture of MSCs with CRC cells, CCL7/CCR1 neutralization/inhibition, ChIP for KLF5-CXCL5 promoter binding, CBP/P300 acetylation assay, TGF-β/SMAD4 pathway analysis, in vivo CRC metastasis models","journal":"Molecular therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-based transcriptional mechanism, acetylation assay, multiple pathway inhibitions, in vivo model, single lab","pmids":["35283273"],"is_preprint":false},{"year":2008,"finding":"Oncostatin M (OSM) stimulates CCL7 and CCL8 expression in primary human dermal fibroblasts via ERK1/2 and p38 MAPK pathways, with p38 prolonging CCL7 mRNA half-life through inhibition of tristetraprolin; constitutive JAK2/STAT5 activation suppressed CCL1 but NOT CCL7 expression, demonstrating that CCL7 transcription is MAPK-dependent but STAT5-independent in fibroblasts.","method":"Primary human dermal fibroblast stimulation with OSM, selective MAPK inhibitors, STAT transcription factor knockdown, tristetraprolin studies, mRNA stability assays","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pathway inhibitors and STAT knockdowns with quantitative mRNA/protein readouts, single lab","pmids":["18981157"],"is_preprint":false},{"year":2014,"finding":"PAR1 antagonism reduces acute LPS-induced neutrophilic lung inflammation by suppressing CCL2 and CCL7 expression (but not CXCL1/CXCL2 or TNF/IL-6); antibody neutralization of both CCL2 and CCL7 reduced LPS-induced leukocyte and neutrophil accumulation; CCL7 was localized by IHC specifically to pulmonary epithelium; intranasal recombinant CCL7 alone recruited neutrophils to airspaces; lung neutrophils had increased CCR1/CCR2 and decreased CXCR2 compared to circulating neutrophils.","method":"Mouse LPS lung inflammation model, PAR1 antagonist treatment, antibody neutralization of CCL2/CCL7, IHC for cellular source, intranasal recombinant CCL7 administration, flow cytometry for chemokine receptor expression on neutrophils","journal":"American journal of respiratory cell and molecular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal in vivo approaches (PAR1 antagonism, combined antibody neutralization, recombinant protein), cellular source identified, receptor switch characterized, replicated across conditions","pmids":["23972264"],"is_preprint":false},{"year":2016,"finding":"CCL7 in psoriatic lesional skin is markedly upregulated compared to other chemokines; keratinocytes and dermal blood endothelial cells are its cellular sources; CCL7 blockade in imiquimod-induced psoriasis-like mouse model reduced myeloid inflammation and key cytokines (CCL20, IL-12p40, IL-17C) and increased IL-4; TNF-α blocker infliximab downregulated CCL7 within 16 hours in human lesional skin, placing CCL7 downstream of TNF-α in Th1/Th17 inflammation.","method":"Quantitative RT-PCR in human skin biopsies, imiquimod mouse model with CCL7 blockade, infliximab human clinical sample analysis, cytokine profiling","journal":"Experimental dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo antibody blockade with cytokine readouts, human clinical intervention data, cellular source identified, single lab","pmids":["25828150"],"is_preprint":false}],"current_model":"CCL7 (MCP-3) is a CC chemokine that functions as a chemotactic factor for monocytes, neutrophils, eosinophils, NK cells, and T lymphocytes by binding multiple chemokine receptors (CCR1, CCR2, CCR3, CCR5, CCR10), with receptor promiscuity enabled by its monomeric structure and distributed GAG-binding epitopes; it acts downstream of TLR9, PAR1, and redox/NFκB/MAPK signaling to orchestrate innate and adaptive immune cell trafficking, can act as a natural CCR5 antagonist, promotes cancer invasion via CCR3-RhoA-MMP-9 and CCR1-JAK/STAT3 axes, drives M1 macrophage polarization through CCR1/JAK2/STAT1 succinylation, and regulates tissue homeostasis including dopamine neuron differentiation, endothelial function via the AKT-eNOS pathway, and ER stress responses indirectly through cellular context."},"narrative":{"mechanistic_narrative":"CCL7 (MCP-3) is a secreted CC chemokine that orchestrates leukocyte trafficking during innate and adaptive immune responses by engaging multiple CC chemokine receptors [PMID:8318676, PMID:7589134, PMID:8642349]. Originally cloned as a monocyte chemoattractant [PMID:8318676], it binds CCR1 [PMID:7545673], CCR2 [PMID:8662823], and CCR5 [PMID:10477718] with high affinity, and its broad receptor promiscuity—encompassing monocytes, T lymphocytes, eosinophils, and neutrophils—rests on a monomeric architecture bearing GAG-binding epitopes distributed across its surface, allowing high-affinity heparan sulfate binding without oligomerization, distinct from CCL2 [PMID:24727473]. Its N-terminus is dispensable for receptor binding but essential for receptor activation, such that N-terminally truncated CCL7 becomes a multi-receptor antagonist [PMID:8631850]; at CCR5 the intact chemokine itself behaves as a natural antagonist, binding without triggering signaling or internalization [PMID:10477718]. In vivo, epithelial- and endothelial-derived CCL7 is a non-redundant driver of eosinophil and neutrophil recruitment in allergic, oxidative, and infectious airway inflammation [PMID:9144514, PMID:11777981, PMID:12107110, PMID:23972264], while contributing additively with CCL2 to CCR2-dependent inflammatory monocyte egress and Th2 restraint during fungal and bacterial infection [PMID:18453605, PMID:19587014], and acting downstream of TLR9 in antifungal immunity [PMID:22422883]. Beyond chemotaxis, CCL7 can negatively regulate neutrophilic inflammation [PMID:30671055] and recruits cDC1 to promote antitumor T cell responses [PMID:33257678]. In cancer, CCL7 promotes invasion and metastasis through CCR3-RhoA-MMP-9-dependent invadopodia maturation [PMID:32217106], CCR1-driven transcriptional feedback and acetylation cascades [PMID:32616889, PMID:35283273], and CCR2-JAK/STAT3 signaling that breaks micrometastatic dormancy [PMID:33986252]. CCL7 also drives macrophage M1 polarization via CCR1/JAK2/STAT1 [PMID:34189838] and via a CCR1-KAT2A-STAT1 succinylation axis linking it to glycolytic reprogramming in lung injury [PMID:40755420], and impairs endothelial function through CCR3 by suppressing AKT-eNOS signaling [PMID:39231238]. Its expression is induced by inflammatory cytokines through NFκB and p38/JNK MAPK pathways [PMID:19577550, PMID:18981157] and by redox-sensitive BRG1-AP-1 chromatin remodeling [PMID:34454163], and is post-transcriptionally controlled by let-7d [PMID:25193015].","teleology":[{"year":1993,"claim":"Establishing CCL7's molecular identity and core activity answered whether it was a distinct chemoattractant, defining it as a CC chemokine that recruits monocytes and is regulated by inflammatory stimuli.","evidence":"cDNA cloning, recombinant expression, chemotaxis and glycosylation analysis, mRNA regulation studies in U937/PBMC","pmids":["8318676"],"confidence":"High","gaps":["Receptors mediating monocyte chemotaxis not yet identified","Neutrophil activity initially absent, later found context-dependent"]},{"year":1994,"claim":"Identifying the murine orthologue (MARC/FIC) enabled in vivo genetic and infection studies of CCL7 function.","evidence":"cDNA library screening from LPS-stimulated WEHI-3 macrophages with human MCP-3 probe and sequencing","pmids":["8002978"],"confidence":"Medium","gaps":["Functional conservation with human CCL7 not directly tested at this stage"]},{"year":1995,"claim":"Defining the receptor repertoire answered how a single chemokine recruits diverse leukocytes, showing CCL7 binds CCR1 and shares receptor sites with MIP-1α/RANTES/MCP-1 while engaging unique sites.","evidence":"CCR1 transfection with radioligand binding and migration assays; primary monocyte/neutrophil binding and cross-desensitization","pmids":["7545673","7589134"],"confidence":"High","gaps":["Full receptor set not enumerated","Structural basis of promiscuity not yet defined"]},{"year":1996,"claim":"Receptor mapping and structure-activity dissection established CCR2 as a murine receptor and showed the N-terminus controls activation versus binding, yielding a multi-receptor antagonist.","evidence":"mCCR2 cloning and radioligand competition; MCP-3(10-76) truncation with binding, chemotaxis and enzyme release assays; leukocyte cross-competition","pmids":["8662823","8631850","8642349"],"confidence":"High","gaps":["Endogenous proteolytic generation of truncated antagonist not demonstrated in vivo","Receptor mediating eosinophil recruitment defined only by shared competition"]},{"year":1999,"claim":"Characterizing CCR5 engagement revealed that CCL7 can act as a natural receptor antagonist, binding without signaling and blocking agonist responses.","evidence":"Radioligand competition, calcium flux, chemotaxis, internalization and HIV infection assays in CCR5 transfectants","pmids":["10477718"],"confidence":"High","gaps":["Physiological relevance of CCR5 antagonism in vivo not established","Weak HIV-inhibitory activity not therapeutically pursued here"]},{"year":2002,"claim":"In vivo neutralization studies established CCL7 as a non-redundant driver of both eosinophil and neutrophil recruitment in airway inflammation, identifying epithelium and endothelium as sources.","evidence":"Mouse OVA, ozone and schistosomal granuloma models with anti-CCL7 neutralization, IHC source localization, IL-4 regulation in cultured endothelium","pmids":["9144514","11777981","12107110"],"confidence":"High","gaps":["Receptor used on recruited neutrophils not resolved at this stage","Relative contribution of epithelial vs endothelial source unclear"]},{"year":2008,"claim":"Genetic knockout and pathway studies defined CCL7's tissue-homeostatic and regulatory roles beyond inflammation, including additive monocyte recruitment with CCL2, dopamine neuron differentiation, and fibroblast collagen production.","evidence":"CCL7-KO Listeria model with monocyte flow cytometry; ventral midbrain precursor cultures with Nurr1-KO; fibroblast collagen/TGFβ and OSM-MAPK studies","pmids":["18453605","18420193","19038247","18981157"],"confidence":"High","gaps":["Single-knockout phenotypes incompletely recapitulate CCR2 loss, indicating redundancy","Direct receptor on dopaminergic precursors inferred from expression"]},{"year":2009,"claim":"Defining cytokine-driven induction pathways established how CCL7 expression is controlled in glia and during fungal infection, and confirmed functional redundancy with CCL2 via CCR2 in suppressing Th2 responses.","evidence":"Rat astrocyte cultures with NFκB/MAPK inhibitors; CCL2-KO/CCR2-KO mice with CCL7 neutralization and IL-4 readouts in Histoplasma infection","pmids":["19577550","19587014"],"confidence":"High","gaps":["Astrocyte signaling defined pharmacologically, not genetically","Mechanism by which CCR2 limits IL-4 not fully resolved"]},{"year":2014,"claim":"Biophysical and post-transcriptional studies answered how CCL7 achieves receptor promiscuity and GAG binding as a monomer and how its abundance is fine-tuned, identifying distributed GAG epitopes and let-7d regulation.","evidence":"Hydroxyl radical footprinting, mutagenesis and SPR with heparan sulfate; luciferase 3'UTR reporter and rescue assays for let-7d in RCC","pmids":["24727473","25193015"],"confidence":"High","gaps":["In vivo consequence of GAG-binding mutations not tested","let-7d regulation shown in one tumor context"]},{"year":2016,"claim":"Cancer studies established CCL7 as a stromal- and tumor-derived driver of invasion and metastasis through defined receptor-effector axes (CCR1/CCR3) and MAPK signaling.","evidence":"CAF/OSCC co-culture with CCR1/CCR3 neutralization; CCL7 overexpression in colon cancer with ERK/JNK inhibitors and xenografts; psoriasis source/blockade studies","pmids":["19937793","27167205","25828150"],"confidence":"Medium","gaps":["Receptor usage varies across tumor types without unifying model","Single-lab xenograft systems"]},{"year":2020,"claim":"Genetic and mechanistic studies resolved divergent context-dependent roles—antitumor cDC1 recruitment, neutrophil suppression, pro-tumor RhoA-MMP-9 invadopodia maturation, dormancy escape, and sterile injury inflammation.","evidence":"CCL7-KO KP/KL lung tumor and reconstitution; CCL7-KO Leishmania model with add-back; RhoA dominant-negative/CA rescue invadopodia assays; CCR2-Co-IP dormancy model; B cell-derived CCL7 AKI model; PAR1/MDSC studies","pmids":["33257678","30671055","32217106","33986252","32737150","23972264","36685592"],"confidence":"High","gaps":["Determinants selecting pro- vs anti-inflammatory/tumor outcome not defined","Receptor-specific signaling bifurcations incompletely mapped"]},{"year":2021,"claim":"Mechanistic dissection linked CCL7 to macrophage polarization, chromatin-level transcriptional control, and glial neuroinflammation, broadening its role to metabolic and epigenetic reprogramming.","evidence":"CCR1/JAK2/STAT1 macrophage M1 studies in AAA; hepatocyte BRG1-AP-1 redox-sensitive transcription with Co-IP/ChIP; astrocyte-microglia CCL7 in TBI","pmids":["34189838","34454163","34293712"],"confidence":"Medium","gaps":["BRG1-AP-1 axis shown in liver only","Glial source mechanisms largely correlative"]},{"year":2024,"claim":"Endothelial-focused genetic studies established CCL7 as a regulator of vascular function and macrophage metabolic reprogramming via CCR3 and CCR1 signaling.","evidence":"EC-specific and global Ccl7 KO in diabetic models with AKT-eNOS pathway analysis; sepsis model with CCR1-KO, KAT2A/STAT1 succinylation and ChIP-based glycolytic gene readouts","pmids":["39231238","40755420"],"confidence":"High","gaps":["Succinylation mechanism reported at abstract-level detail","Translation of endothelial CCL7 axis to human disease not established"]},{"year":null,"claim":"The molecular determinants that switch CCL7 between agonist and antagonist behavior at shared receptors, and between pro- and anti-inflammatory or pro- and antitumor outcomes in different tissues, remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model linking receptor choice to functional outcome","Structural basis of biased signaling not defined","In vivo relevance of natural antagonism untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[2,3,6,21,25]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[5,8]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,7,9,38]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[7,11,17,25]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[2,3,6]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,4,8,30,32]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[21,27,34,35]}],"complexes":[],"partners":["CCR1","CCR2","CCR3","CCR5"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P80098","full_name":"C-C motif chemokine 7","aliases":["Monocyte chemoattractant protein 3","Monocyte chemotactic protein 3","MCP-3","NC28","Small-inducible cytokine A7"],"length_aa":99,"mass_kda":11.2,"function":"Chemotactic factor that plays an important role in immune regulation. Attracts monocytes, eosinophils, basophils, and T-cells to sites of inflammation or infection. Upon binding to various chemokine receptors including CCR1, CCR2, CCR3, and CCR5, facilitates immune cell migration by guiding them to infected tissues (PubMed:9364936, PubMed:10477718). Interacts with CCR2 to facilitate the release of monocytes from the bone marrow into the bloodstream, maintaining monocyte homeostasis. In turn, monocytes recruited to inflamed or injured tissues can differentiate into macrophages or dendritic cells, which are essential for immune defense and tissue repair. Through CCR1, contributes to macrophage polarization via NF-kappa-B activation which leads to the release of inflammatory factors (PubMed:38417634). In the trigeminal ganglion neurons, activates ERK via CCR2 and CCR3 to enhance neuronal excitability, which contributes to the maintenance of trigeminal neuropathic pain. Additionally, modulates the early immune response in the skin, preventing pathogen dissemination while maintaining cutaneous immune control","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P80098/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CCL7","classification":"Not Classified","n_dependent_lines":10,"n_total_lines":1208,"dependency_fraction":0.008278145695364239},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CCL7","total_profiled":1310},"omim":[{"mim_id":"621526","title":"GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE-LIKE PROTEIN; QPCTL","url":"https://www.omim.org/entry/621526"},{"mim_id":"609423","title":"HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/609423"},{"mim_id":"606278","title":"F-BOX AND WD40 DOMAIN PROTEIN 7; FBXW7","url":"https://www.omim.org/entry/606278"},{"mim_id":"601391","title":"CHEMOKINE, CC MOTIF, LIGAND 13; CCL13","url":"https://www.omim.org/entry/601391"},{"mim_id":"601156","title":"CHEMOKINE, CC MOTIF, LIGAND 11; CCL11","url":"https://www.omim.org/entry/601156"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"bone marrow","ntpm":24.4}],"url":"https://www.proteinatlas.org/search/CCL7"},"hgnc":{"alias_symbol":["MCP-3","NC28","FIC","MARC","MCP3"],"prev_symbol":["SCYA6","SCYA7"]},"alphafold":{"accession":"P80098","domains":[{"cath_id":"2.40.50.40","chopping":"35-99","consensus_level":"medium","plddt":91.4245,"start":35,"end":99}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P80098","model_url":"https://alphafold.ebi.ac.uk/files/AF-P80098-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P80098-F1-predicted_aligned_error_v6.png","plddt_mean":84.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CCL7","jax_strain_url":"https://www.jax.org/strain/search?query=CCL7"},"sequence":{"accession":"P80098","fasta_url":"https://rest.uniprot.org/uniprotkb/P80098.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P80098/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P80098"}},"corpus_meta":[{"pmid":"32360286","id":"PMC_32360286","title":"Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19.","date":"2020","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32360286","citation_count":521,"is_preprint":false},{"pmid":"9655469","id":"PMC_9655469","title":"MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study.","date":"1998","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/9655469","citation_count":307,"is_preprint":false},{"pmid":"10433925","id":"PMC_10433925","title":"Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis.","date":"1999","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10433925","citation_count":230,"is_preprint":false},{"pmid":"10477718","id":"PMC_10477718","title":"CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist.","date":"1999","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10477718","citation_count":230,"is_preprint":false},{"pmid":"19362538","id":"PMC_19362538","title":"The fic domain: regulation of cell signaling by adenylylation.","date":"2009","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/19362538","citation_count":220,"is_preprint":false},{"pmid":"18453605","id":"PMC_18453605","title":"Additive roles for MCP-1 and MCP-3 in CCR2-mediated recruitment of inflammatory monocytes during Listeria monocytogenes infection.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18453605","citation_count":206,"is_preprint":false},{"pmid":"19577550","id":"PMC_19577550","title":"Inflammatory cytokines stimulate the chemokines CCL2/MCP-1 and CCL7/MCP-3 through NFkB and MAPK dependent pathways in rat astrocytes [corrected].","date":"2009","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/19577550","citation_count":186,"is_preprint":false},{"pmid":"8642349","id":"PMC_8642349","title":"Monocyte chemotactic protein 4 (MCP-4), a novel structural and functional analogue of MCP-3 and eotaxin.","date":"1996","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8642349","citation_count":150,"is_preprint":false},{"pmid":"24141193","id":"PMC_24141193","title":"The Fic protein Doc uses an inverted substrate to phosphorylate and inactivate EF-Tu.","date":"2013","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/24141193","citation_count":148,"is_preprint":false},{"pmid":"19937793","id":"PMC_19937793","title":"Tumor-stromal crosstalk in invasion of oral squamous cell carcinoma: a pivotal role of CCL7.","date":"2010","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19937793","citation_count":142,"is_preprint":false},{"pmid":"22266942","id":"PMC_22266942","title":"Adenylylation control by intra- or intermolecular active-site obstruction in Fic proteins.","date":"2012","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/22266942","citation_count":141,"is_preprint":false},{"pmid":"8631850","id":"PMC_8631850","title":"RANTES and MCP-3 antagonists bind multiple chemokine receptors.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8631850","citation_count":136,"is_preprint":false},{"pmid":"19424580","id":"PMC_19424580","title":"Tumor-associated macrophage/microglia infiltration in human gliomas is correlated with MCP-3, but not MCP-1.","date":"2009","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19424580","citation_count":128,"is_preprint":false},{"pmid":"7545673","id":"PMC_7545673","title":"Monocyte chemotactic protein-3 (MCP3) interacts with multiple leukocyte receptors. C-C CKR1, a receptor for macrophage inflammatory protein-1 alpha/Rantes, is also a functional receptor for MCP3.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7545673","citation_count":126,"is_preprint":false},{"pmid":"19503829","id":"PMC_19503829","title":"Fido, a novel AMPylation domain common to fic, doc, and AvrB.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19503829","citation_count":116,"is_preprint":false},{"pmid":"29915688","id":"PMC_29915688","title":"Crucial biological functions of CCL7 in cancer.","date":"2018","source":"PeerJ","url":"https://pubmed.ncbi.nlm.nih.gov/29915688","citation_count":106,"is_preprint":false},{"pmid":"25395623","id":"PMC_25395623","title":"Unfolded protein response-regulated Drosophila Fic (dFic) protein reversibly AMPylates BiP chaperone during endoplasmic reticulum homeostasis.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25395623","citation_count":106,"is_preprint":false},{"pmid":"11777981","id":"PMC_11777981","title":"CCL7 and CXCL10 orchestrate oxidative stress-induced neutrophilic lung inflammation.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11777981","citation_count":104,"is_preprint":false},{"pmid":"33257678","id":"PMC_33257678","title":"CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33257678","citation_count":100,"is_preprint":false},{"pmid":"25601083","id":"PMC_25601083","title":"A novel link between Fic (filamentation induced by cAMP)-mediated adenylylation/AMPylation and the unfolded protein response.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25601083","citation_count":96,"is_preprint":false},{"pmid":"8662823","id":"PMC_8662823","title":"Cloning and functional expression of mCCR2, a murine receptor for the C-C chemokines JE and FIC.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8662823","citation_count":94,"is_preprint":false},{"pmid":"25193015","id":"PMC_25193015","title":"Let-7d suppresses growth, metastasis, and tumor macrophage infiltration in renal cell carcinoma by targeting COL3A1 and CCL7.","date":"2014","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25193015","citation_count":91,"is_preprint":false},{"pmid":"27167205","id":"PMC_27167205","title":"Crosstalk between CCL7 and CCR3 promotes metastasis of colon cancer cells via ERK-JNK signaling pathways.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27167205","citation_count":90,"is_preprint":false},{"pmid":"23972264","id":"PMC_23972264","title":"Proteinase-activated receptor-1, CCL2, and CCL7 regulate acute neutrophilic lung inflammation.","date":"2014","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23972264","citation_count":88,"is_preprint":false},{"pmid":"20622875","id":"PMC_20622875","title":"Structural basis of Fic-mediated adenylylation.","date":"2010","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20622875","citation_count":82,"is_preprint":false},{"pmid":"19587014","id":"PMC_19587014","title":"The CCL7-CCL2-CCR2 axis regulates IL-4 production in lungs and fungal immunity.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19587014","citation_count":78,"is_preprint":false},{"pmid":"7589134","id":"PMC_7589134","title":"Monocyte chemotactic protein-3 (MCP3) interacts with multiple leukocyte receptors: binding and signaling of MCP3 through shared as well as unique receptors on monocytes and neutrophils.","date":"1995","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7589134","citation_count":77,"is_preprint":false},{"pmid":"8318676","id":"PMC_8318676","title":"Molecular cloning of the MCP-3 chemokine gene and regulation of its expression.","date":"1993","source":"European cytokine network","url":"https://pubmed.ncbi.nlm.nih.gov/8318676","citation_count":75,"is_preprint":false},{"pmid":"2546924","id":"PMC_2546924","title":"Nucleotide sequences of fic and fic-1 genes involved in cell filamentation induced by cyclic AMP in Escherichia coli.","date":"1989","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/2546924","citation_count":74,"is_preprint":false},{"pmid":"22544313","id":"PMC_22544313","title":"Visual neurotransmission in Drosophila requires expression of Fic in glial capitate projections.","date":"2012","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/22544313","citation_count":65,"is_preprint":false},{"pmid":"14571188","id":"PMC_14571188","title":"MCP-1-MCP-3-Eotaxin gene cluster influences HIV-1 transmission.","date":"2003","source":"AIDS (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/14571188","citation_count":61,"is_preprint":false},{"pmid":"24507752","id":"PMC_24507752","title":"The many faces of Fic: structural and functional aspects of Fic enzymes.","date":"2014","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24507752","citation_count":60,"is_preprint":false},{"pmid":"31003094","id":"PMC_31003094","title":"Chemokines CCL2 and CCL7, but not CCL12, play a significant role in the development of pain-related behavior and opioid-induced analgesia.","date":"2019","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/31003094","citation_count":59,"is_preprint":false},{"pmid":"9144514","id":"PMC_9144514","title":"Monocyte chemotactic protein-3 (MCP-3)/fibroblast-induced cytokine (FIC) in eosinophilic inflammation of the airways and the inhibitory effects of an anti-MCP-3/FIC antibody.","date":"1997","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9144514","citation_count":57,"is_preprint":false},{"pmid":"25425164","id":"PMC_25425164","title":"The mammalian molybdenum enzymes of mARC.","date":"2014","source":"Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25425164","citation_count":56,"is_preprint":false},{"pmid":"20176790","id":"PMC_20176790","title":"Histophilus somni IbpA DR2/Fic in virulence and immunoprotection at the natural host alveolar epithelial barrier.","date":"2010","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/20176790","citation_count":54,"is_preprint":false},{"pmid":"19293428","id":"PMC_19293428","title":"Bacterial FIC Proteins AMP Up Infection.","date":"2009","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/19293428","citation_count":53,"is_preprint":false},{"pmid":"33160071","id":"PMC_33160071","title":"The CCL2/CCL7/CCL12/CCR2 pathway is substantially and persistently upregulated in mice after traumatic brain injury, and CCL2 modulates the complement system in microglia.","date":"2020","source":"Molecular and cellular probes","url":"https://pubmed.ncbi.nlm.nih.gov/33160071","citation_count":53,"is_preprint":false},{"pmid":"25034237","id":"PMC_25034237","title":"The role of CXCL12 and CCL7 chemokines in immune regulation, embryonic development, and tissue regeneration.","date":"2014","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/25034237","citation_count":51,"is_preprint":false},{"pmid":"8980953","id":"PMC_8980953","title":"Increased expression of mRNA encoding RANTES and MCP-3 in the bronchial mucosa in atopic asthma.","date":"1996","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/8980953","citation_count":50,"is_preprint":false},{"pmid":"36685592","id":"PMC_36685592","title":"Glioma-derived CCL2 and CCL7 mediate migration of immune suppressive CCR2+/CX3CR1+ M-MDSCs into the tumor microenvironment in a redundant manner.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36685592","citation_count":49,"is_preprint":false},{"pmid":"25435325","id":"PMC_25435325","title":"Crystal structure of the human, FIC-domain containing protein HYPE and implications for its functions.","date":"2014","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/25435325","citation_count":47,"is_preprint":false},{"pmid":"6284712","id":"PMC_6284712","title":"Involvement of cyclic AMP and its receptor protein in filamentation of an Escherichia coli fic mutant.","date":"1982","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/6284712","citation_count":47,"is_preprint":false},{"pmid":"21942410","id":"PMC_21942410","title":"The fourth mammalian molybdenum enzyme mARC: current state of research.","date":"2011","source":"Drug metabolism reviews","url":"https://pubmed.ncbi.nlm.nih.gov/21942410","citation_count":46,"is_preprint":false},{"pmid":"1656497","id":"PMC_1656497","title":"Functional analysis of the fic gene involved in regulation of cell division.","date":"1991","source":"Research in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/1656497","citation_count":46,"is_preprint":false},{"pmid":"27138431","id":"PMC_27138431","title":"The Caenorhabditis elegans Protein FIC-1 Is an AMPylase That Covalently Modifies Heat-Shock 70 Family Proteins, Translation Elongation Factors and Histones.","date":"2016","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27138431","citation_count":43,"is_preprint":false},{"pmid":"22422883","id":"PMC_22422883","title":"Early induction of CCL7 downstream of TLR9 signaling promotes the development of robust immunity to cryptococcal infection.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22422883","citation_count":43,"is_preprint":false},{"pmid":"18420193","id":"PMC_18420193","title":"The beta-chemokines CCL2 and CCL7 are two novel differentiation factors for midbrain dopaminergic precursors and neurons.","date":"2008","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/18420193","citation_count":42,"is_preprint":false},{"pmid":"24727473","id":"PMC_24727473","title":"Multiple glycosaminoglycan-binding epitopes of monocyte chemoattractant protein-3/CCL7 enable it to function as a non-oligomerizing chemokine.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24727473","citation_count":42,"is_preprint":false},{"pmid":"29089387","id":"PMC_29089387","title":"Fic-mediated deAMPylation is not dependent on homodimerization and rescues toxic AMPylation in flies.","date":"2017","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29089387","citation_count":42,"is_preprint":false},{"pmid":"34189838","id":"PMC_34189838","title":"CCL7 contributes to angiotensin II-induced abdominal aortic aneurysm by promoting macrophage infiltration and pro-inflammatory phenotype.","date":"2021","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34189838","citation_count":41,"is_preprint":false},{"pmid":"17154174","id":"PMC_17154174","title":"MCP-3 (CCL7) delivered by parvovirus MVMp reduces tumorigenicity of mouse melanoma cells through activation of T lymphocytes and NK cells.","date":"2007","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17154174","citation_count":41,"is_preprint":false},{"pmid":"25847975","id":"PMC_25847975","title":"CCL7 and IRF-7 Mediate Hallmark Inflammatory and IFN Responses following Rhinovirus 1B Infection.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25847975","citation_count":40,"is_preprint":false},{"pmid":"34293712","id":"PMC_34293712","title":"Astrocyte-derived CCL7 promotes microglia-mediated inflammation following traumatic brain injury.","date":"2021","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34293712","citation_count":40,"is_preprint":false},{"pmid":"12885941","id":"PMC_12885941","title":"Expression of L-CCR in HEK 293 cells reveals functional responses to CCL2, CCL5, CCL7, and CCL8.","date":"2003","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/12885941","citation_count":40,"is_preprint":false},{"pmid":"31034889","id":"PMC_31034889","title":"Alpha-Synuclein Is a Target of Fic-Mediated Adenylylation/AMPylation: Possible Implications for Parkinson's Disease.","date":"2019","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/31034889","citation_count":39,"is_preprint":false},{"pmid":"24878990","id":"PMC_24878990","title":"MiR-506 inhibits PRRSV replication in MARC-145 cells via CD151.","date":"2014","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24878990","citation_count":39,"is_preprint":false},{"pmid":"26299785","id":"PMC_26299785","title":"Structure and function of Fic proteins.","date":"2015","source":"Nature reviews. Microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/26299785","citation_count":38,"is_preprint":false},{"pmid":"32737150","id":"PMC_32737150","title":"B Lymphocyte-Derived CCL7 Augments Neutrophil and Monocyte Recruitment, Exacerbating Acute Kidney Injury.","date":"2020","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/32737150","citation_count":38,"is_preprint":false},{"pmid":"30671055","id":"PMC_30671055","title":"CCL7 Is a Negative Regulator of Cutaneous Inflammation Following Leishmania major Infection.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30671055","citation_count":38,"is_preprint":false},{"pmid":"16344498","id":"PMC_16344498","title":"Serum levels of monocyte chemotactic protein-3/CCL7 are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis.","date":"2006","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/16344498","citation_count":38,"is_preprint":false},{"pmid":"32616889","id":"PMC_32616889","title":"SOX18 promotes gastric cancer metastasis through transactivating MCAM and CCL7.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32616889","citation_count":37,"is_preprint":false},{"pmid":"34454163","id":"PMC_34454163","title":"Redox-sensitive activation of CCL7 by BRG1 in hepatocytes during liver injury.","date":"2021","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/34454163","citation_count":36,"is_preprint":false},{"pmid":"12107110","id":"PMC_12107110","title":"Eosinophil recruitment in type-2 hypersensitivity pulmonary granulomas: source and contribution of monocyte chemotactic protein-3 (CCL7).","date":"2002","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12107110","citation_count":36,"is_preprint":false},{"pmid":"28497908","id":"PMC_28497908","title":"The molybdenum cofactor enzyme mARC: Moonlighting or promiscuous enzyme?","date":"2017","source":"BioFactors (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/28497908","citation_count":35,"is_preprint":false},{"pmid":"27226123","id":"PMC_27226123","title":"Mcp3 is a novel mitochondrial outer membrane protein that follows a unique IMP-dependent biogenesis pathway.","date":"2016","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/27226123","citation_count":35,"is_preprint":false},{"pmid":"24928048","id":"PMC_24928048","title":"Porcine reproductive and respiratory syndrome virus infection activates NOD2-RIP2 signal pathway in MARC-145 cells.","date":"2014","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/24928048","citation_count":35,"is_preprint":false},{"pmid":"25828150","id":"PMC_25828150","title":"CCL7 contributes to the TNF-alpha-dependent inflammation of lesional psoriatic skin.","date":"2015","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/25828150","citation_count":35,"is_preprint":false},{"pmid":"32060844","id":"PMC_32060844","title":"CCL7 Signaling in the Tumor Microenvironment.","date":"2020","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/32060844","citation_count":34,"is_preprint":false},{"pmid":"35283273","id":"PMC_35283273","title":"CCL7 and TGF-β secreted by MSCs play opposite roles in regulating CRC metastasis in a KLF5/CXCL5-dependent manner.","date":"2022","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/35283273","citation_count":34,"is_preprint":false},{"pmid":"8002978","id":"PMC_8002978","title":"Mouse macrophage derived monocyte chemotactic protein-3: cDNA cloning and identification as MARC/FIC.","date":"1994","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/8002978","citation_count":34,"is_preprint":false},{"pmid":"27482742","id":"PMC_27482742","title":"Biological Diversity and Molecular Plasticity of FIC Domain Proteins.","date":"2016","source":"Annual review of microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/27482742","citation_count":33,"is_preprint":false},{"pmid":"32217106","id":"PMC_32217106","title":"The chemokine CCL7 regulates invadopodia maturation and MMP-9 mediated collagen degradation in liver-metastatic carcinoma cells.","date":"2020","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/32217106","citation_count":33,"is_preprint":false},{"pmid":"33986252","id":"PMC_33986252","title":"Inhibition of CCL7 derived from Mo-MDSCs prevents metastatic progression from latency in colorectal cancer.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33986252","citation_count":33,"is_preprint":false},{"pmid":"23738009","id":"PMC_23738009","title":"Conserved inhibitory mechanism and competent ATP binding mode for adenylyltransferases with Fic fold.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23738009","citation_count":33,"is_preprint":false},{"pmid":"29617857","id":"PMC_29617857","title":"FIC proteins: from bacteria to humans and back again.","date":"2018","source":"Pathogens and disease","url":"https://pubmed.ncbi.nlm.nih.gov/29617857","citation_count":32,"is_preprint":false},{"pmid":"36118415","id":"PMC_36118415","title":"LINC01094/SPI1/CCL7 Axis Promotes Macrophage Accumulation in Lung Adenocarcinoma and Tumor Cell Dissemination.","date":"2022","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/36118415","citation_count":30,"is_preprint":false},{"pmid":"33268540","id":"PMC_33268540","title":"Comparison of ZMAC and MARC-145 Cell Lines for Improving Porcine Reproductive and Respiratory Syndrome Virus Isolation from Clinical Samples.","date":"2021","source":"Journal of clinical microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/33268540","citation_count":30,"is_preprint":false},{"pmid":"31121231","id":"PMC_31121231","title":"Structural analysis and biological activity of cell wall polysaccharides extracted from Panax ginseng marc.","date":"2019","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/31121231","citation_count":30,"is_preprint":false},{"pmid":"26814232","id":"PMC_26814232","title":"Identification of Fic-1 as an enzyme that inhibits bacterial DNA replication by AMPylating GyrB, promoting filament formation.","date":"2016","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/26814232","citation_count":29,"is_preprint":false},{"pmid":"30850593","id":"PMC_30850593","title":"A Ca2+-regulated deAMPylation switch in human and bacterial FIC proteins.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30850593","citation_count":28,"is_preprint":false},{"pmid":"19038247","id":"PMC_19038247","title":"Cross-talk between MCP-3 and TGFbeta promotes fibroblast collagen biosynthesis.","date":"2008","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/19038247","citation_count":28,"is_preprint":false},{"pmid":"2842288","id":"PMC_2842288","title":"Cloning of the fic-1 gene involved in cell filamentation induced by cyclic AMP and construction of a delta fic Escherichia coli strain.","date":"1988","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/2842288","citation_count":28,"is_preprint":false},{"pmid":"18981157","id":"PMC_18981157","title":"Oncostatin M-induced and constitutive activation of the JAK2/STAT5/CIS pathway suppresses CCL1, but not CCL7 and CCL8, chemokine expression.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18981157","citation_count":28,"is_preprint":false},{"pmid":"26378779","id":"PMC_26378779","title":"Expression and Function of mARC: Roles in Lipogenesis and Metabolic Activation of Ximelagatran.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26378779","citation_count":28,"is_preprint":false},{"pmid":"31518371","id":"PMC_31518371","title":"Irisin promotes C2C12 myoblast proliferation via ERK-dependent CCL7 upregulation.","date":"2019","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/31518371","citation_count":27,"is_preprint":false},{"pmid":"29174638","id":"PMC_29174638","title":"Upregulation of CCL7 and CCL2 in reward system mediated through dopamine D1 receptor signaling underlies methamphetamine-induced place preference in mice.","date":"2017","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/29174638","citation_count":27,"is_preprint":false},{"pmid":"21279498","id":"PMC_21279498","title":"MCP-3/CCL7 production by astrocytes: implications for SIV neuroinvasion and AIDS encephalitis.","date":"2011","source":"Journal of neurovirology","url":"https://pubmed.ncbi.nlm.nih.gov/21279498","citation_count":26,"is_preprint":false},{"pmid":"26787847","id":"PMC_26787847","title":"Intrinsic regulation of FIC-domain AMP-transferases by oligomerization and automodification.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/26787847","citation_count":24,"is_preprint":false},{"pmid":"30788000","id":"PMC_30788000","title":"High CCL7 expression is associated with migration, invasion and bone metastasis of non-small cell lung cancer cells.","date":"2019","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/30788000","citation_count":24,"is_preprint":false},{"pmid":"36076613","id":"PMC_36076613","title":"3,5-Dicaffeoylquinic acid attenuates microglial activation-mediated inflammatory pain by enhancing autophagy through the suppression of MCP3/JAK2/STAT3 signaling.","date":"2022","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/36076613","citation_count":23,"is_preprint":false},{"pmid":"23872063","id":"PMC_23872063","title":"Dual effect of chemokine CCL7/MCP-3 in the development of renal tubulointerstitial fibrosis.","date":"2013","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/23872063","citation_count":23,"is_preprint":false},{"pmid":"30545001","id":"PMC_30545001","title":"From the Eukaryotic Molybdenum Cofactor Biosynthesis to the Moonlighting Enzyme mARC.","date":"2018","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/30545001","citation_count":23,"is_preprint":false},{"pmid":"36274485","id":"PMC_36274485","title":"The role of CCL2, CCL7, ICAM-1, and VCAM-1 in interaction of endothelial cells and natural killer cells.","date":"2022","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36274485","citation_count":22,"is_preprint":false},{"pmid":"27956527","id":"PMC_27956527","title":"Role of CCL7 in Type I Hypersensitivity Reactions in Murine Experimental Allergic Conjunctivitis.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/27956527","citation_count":22,"is_preprint":false},{"pmid":"39231238","id":"PMC_39231238","title":"Inhibition of CCL7 improves endothelial dysfunction and vasculopathy in mouse models of diabetes mellitus.","date":"2024","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39231238","citation_count":21,"is_preprint":false},{"pmid":"40755420","id":"PMC_40755420","title":"Endothelial-Derived CCL7 Promotes Macrophage Polarization and Aggravates Septic Acute Lung Injury via CCR1-Mediated STAT1 Succinylation.","date":"2025","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/40755420","citation_count":20,"is_preprint":false},{"pmid":"35914137","id":"PMC_35914137","title":"Fic-mediated AMPylation tempers the unfolded protein response during physiological stress.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/35914137","citation_count":20,"is_preprint":false},{"pmid":"37021908","id":"PMC_37021908","title":"HDAC2 exacerbates rheumatoid arthritis progression via the IL-17-CCL7 signaling pathway.","date":"2023","source":"Environmental toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/37021908","citation_count":20,"is_preprint":false},{"pmid":"32632184","id":"PMC_32632184","title":"Identification of targets of AMPylating Fic enzymes by co-substrate-mediated covalent capture.","date":"2020","source":"Nature chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32632184","citation_count":20,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50068,"output_tokens":10984,"usd":0.157482,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":21893,"output_tokens":4843,"usd":0.11527,"stage2_stop_reason":"end_turn"},"total_usd":0.272752,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"CCL7 (MCP-3/NC28) was molecularly cloned and identified as a CC chemokine with chemotactic activity for monocytes but not neutrophils; unlike MCP-1, the secreted MCP-3 protein is N-glycosylated. Expression is induced by PMA in U937 cells and super-induced by cycloheximide, and co-regulated with MCP-1 by IFN-γ and IL-13 in PBMC.\",\n      \"method\": \"cDNA cloning, recombinant protein expression, chemotaxis assay, glycosylation analysis, Northern blot/mRNA regulation studies\",\n      \"journal\": \"European cytokine network\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — original cloning paper with functional reconstitution (chemotaxis assay), biochemical characterization (glycosylation), and regulatory studies; foundational result replicated across subsequent literature\",\n      \"pmids\": [\"8318676\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Mouse MCP-3 was identified as the MARC/FIC protein; a cDNA library from LPS-stimulated WEHI-3 macrophages yielded a sequence identical to mouse MARC, establishing MARC/FIC as the murine orthologue of human CCL7.\",\n      \"method\": \"cDNA library screening with human MCP-3 probe, sequencing\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct cDNA cloning with sequence identity confirmation, single lab\",\n      \"pmids\": [\"8002978\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"CCL7 (MCP-3) binds CCR1 (C-C CKR1) as a functional high-affinity receptor: recombinant CCR1-expressing 293 cells bound 125I-MCP-3, MCP-3 induced directional migration of CCR1/293 cells, and MCP-3, MIP-1α, and RANTES cross-competed for binding and cross-desensitized migration responses.\",\n      \"method\": \"Stable transfection of CCR1 cDNA in HEK293 cells, 125I-radioligand binding competition, in vitro chemotaxis assay, calcium flux/desensitization\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted receptor-ligand interaction in defined transfected cells with radioligand binding and functional migration assays\",\n      \"pmids\": [\"7545673\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"CCL7 (MCP-3) binds monocytes with high affinity (Kd ~1–3 nM, ~10,000 sites/cell) and signals through multiple CC chemokine receptors shared with MIP-1α, RANTES, and MCP-1, but also through receptor sites unique to MCP-3 (including sites shared with MIP-1β); MCP-3 was the only CC chemokine that consistently chemoattracted neutrophils in this study, implying a unique receptor on neutrophils.\",\n      \"method\": \"125I-MCP-3 radioligand binding on primary monocytes and neutrophils, calcium flux cross-desensitization, in vitro chemotaxis\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (binding, calcium flux, chemotaxis) on primary cells; replicated by subsequent receptor-cloning studies\",\n      \"pmids\": [\"7589134\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Murine CCR2 (mCCR2) was cloned and shown to bind mouse FIC (mouse CCL7) with high affinity; 125I-JE (mMCP-1) binding to mCCR2-expressing HEK293 cells was competed by FIC but not by MIP-1α, C10, or N51/KC, establishing mCCR2 as a functional receptor for mouse CCL7.\",\n      \"method\": \"cDNA cloning, stable expression in HEK293 cells, 125I radioligand binding competition\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct receptor-ligand binding reconstituted in defined cell system with radioligand competition\",\n      \"pmids\": [\"8662823\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"N-terminally truncated CCL7 analog MCP-3(10–76) acts as a multi-receptor antagonist: it binds CCL7, MCP-1, and RANTES binding sites on THP-1 monocytes with high affinity but lacks chemotactic activity, inhibiting responses to all three chemokines, demonstrating that the N-terminus of CCL7 is critical for receptor activation but not binding.\",\n      \"method\": \"Radioligand binding competition on THP-1 cells, in vitro chemotaxis, enzyme release assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — structure-activity mutagenesis (N-terminal truncation) combined with binding and functional assays\",\n      \"pmids\": [\"8631850\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"CCL7 (MCP-4 comparison study) acts as a potent chemoattractant for monocytes and T lymphocytes via shared MCP-1/MCP-3/RANTES receptors, and for eosinophils via eotaxin-shared receptors, establishing CCL7's broad receptor promiscuity across leukocyte subsets.\",\n      \"method\": \"Radioligand binding cross-competition, chemotaxis assay, cross-desensitization on purified leukocyte populations\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional receptor profiling in context of MCP-4 characterization; CCL7 data are direct comparisons\",\n      \"pmids\": [\"8642349\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CCL7 (MCP-3/FIC) is expressed predominantly in airway epithelium after allergen challenge; pre-treatment with anti-MCP-3/FIC antibody significantly inhibited OVA-induced eosinophilia in bronchoalveolar lavage (46% eosinophils in control vs 8% with anti-CCL7), establishing a functional role for CCL7 in eosinophil recruitment in allergic airway inflammation.\",\n      \"method\": \"Mouse OVA sensitization/challenge model, immunocytochemistry for cellular source, RT-PCR, antibody neutralization in vivo, BAL differential cell counts\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — antibody neutralization in vivo with quantitative cellular readout; source localization by immunostaining; replicated by subsequent studies\",\n      \"pmids\": [\"9144514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CCL7 (MCP-3) binds CCR5 with high affinity (IC50 ~2.14 nM competing 125I-MIP-1β) but acts as a natural antagonist: it binds CCR5 without inducing functional responses (calcium flux, chemotaxis), fails to cause CCR5 endocytosis, and inhibits CCR5 activation by MIP-1β. It was a weak inhibitor of HIV infection despite blocking gp120 binding.\",\n      \"method\": \"Radioligand (125I-MIP-1β) competition binding on CCR5-stable transfectants, calcium flux assay, chemotaxis assay, receptor internalization assay, HIV infection inhibition assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal assays (binding, calcium, chemotaxis, internalization, HIV infection) in defined transfected cell system, single lab with rigorous controls\",\n      \"pmids\": [\"10477718\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CCL7 orchestrates oxidative stress-induced neutrophilic airway inflammation: ozone exposure up-regulated CCL7 protein in lung with airway epithelium as primary source; anti-CCL7 antibody decreased neutrophil recruitment by 63%, establishing a non-redundant role for CCL7 in neutrophil (not only monocyte) recruitment in vivo.\",\n      \"method\": \"Mouse ozone-exposure model, lung mRNA/protein quantification by RT-PCR/ELISA, IHC for cellular source, in vivo antibody neutralization, BAL differential cell counting\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo antibody neutralization with quantitative cellular phenotype; source identified by IHC; replicated in subsequent lung inflammation studies\",\n      \"pmids\": [\"11777981\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CCL7 (MCP-3) contributes 40–50% of eosinophil recruitment in type-2 (Th2-mediated, schistosomal antigen) pulmonary granulomas; endothelial cells in and near granulomas are a major in situ source of CCL7, and IL-4 drives maximal CCL7 expression from cultured mouse lung endothelial cells.\",\n      \"method\": \"Mouse pulmonary granuloma model, in vivo antibody neutralization, immunohistochemistry for source, IL-4 neutralization, cultured endothelial cell MCP-3 production assay\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo neutralization with quantitative eosinophil readout, source identified by IHC, mechanism (IL-4 regulation) confirmed in vitro\",\n      \"pmids\": [\"12107110\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CCL7 and MCP-1 (CCL2) provide additive, parallel contributions to CCR2-mediated Ly6C(high) inflammatory monocyte recruitment from bone marrow during Listeria monocytogenes infection; MCP-3−/− mice had fewer splenic and circulating Ly6C(high) monocytes, increased bone marrow monocytes, and fewer Tip-DCs, paralleling MCP-1−/− phenotype but not fully recapitulated by either single knockout.\",\n      \"method\": \"CCL7 knockout mice, L. monocytogenes infection model, flow cytometry for monocyte subsets, intracellular cytokine staining for Tip-DCs, bacterial burden quantification\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO model with defined cellular and in vivo phenotype, multiple outcome measures, comparison with CCL2-KO and CCR2-KO\",\n      \"pmids\": [\"18453605\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CCL7 and CCL2 selectively promote differentiation of Nurr1+ precursors into midbrain dopamine neurons and enhance neuritogenesis, acting via CCR1 and CCR2 expressed in the ventral midbrain; CCL7 expression is developmentally regulated and reduced in Nurr1 knockout mice.\",\n      \"method\": \"Primary ventral midbrain precursor cultures, CCL2/CCL7 treatment, immunofluorescence for TH+ neurons, Nurr1-KO mouse analysis, developmental mRNA expression analysis\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined in vitro differentiation assay, genetic model (Nurr1-KO), single lab\",\n      \"pmids\": [\"18420193\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CCL7 (MCP-3) promotes type I collagen secretion by fibroblasts through activation of TGFβ signaling/MAPK pathways; TGFβ1 in turn stimulates CCL7 gene expression in fibroblasts, creating a positive feedback loop; microarray analysis confirmed additive effects on key TGFβ-regulated transcripts (PAI-1, OSF2, IGFBP6).\",\n      \"method\": \"Recombinant MCP-3 treatment of fibroblasts, collagen secretion assay, MAPK pathway inhibitor experiments, TGFβ signaling analysis (Smad phosphorylation), microarray, qRT-PCR\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pathway analyses in fibroblast cultures with functional collagen readout, single lab\",\n      \"pmids\": [\"19038247\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"IL-1β and TNF-α stimulate CCL7 protein production in rat astrocytes through NFκB and p38/JNK MAPK pathways (but not ERK); selective inhibitors of NFκB (MG-132, SC-514) and p38/JNK (SB203580, SP600125) blocked cytokine-induced CCL7 upregulation, establishing signaling pathways for astrocytic CCL7 induction.\",\n      \"method\": \"Primary rat astrocyte cultures, ELISA for CCL7/CCL2, selective pharmacological inhibitors of NFκB (MG-132, SC-514) and MAPK pathways\",\n      \"journal\": \"Brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway dissection with multiple inhibitors and quantitative protein output, single lab\",\n      \"pmids\": [\"19577550\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CCL7 and CCL2 together regulate the CCR2 pathway to limit IL-4 generation and control host resistance to Histoplasma capsulatum: CCL7 neutralization in CCL2−/− mice (but not wild-type) resulted in increased IL-4 production and elevated fungal burden, demonstrating functional redundancy between CCL7 and CCL2 via CCR2 in suppressing Th2 responses.\",\n      \"method\": \"CCL2-KO mice, CCR2-KO mice, in vivo CCL7 antibody neutralization, IL-4 ELISA/intracellular staining, arginase/YM1 transcription analysis, fungal burden quantification\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic and antibody neutralization approaches combined, defined mechanistic outcome (IL-4 regulation via CCR2), multiple orthogonal readouts\",\n      \"pmids\": [\"19587014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CCL7 is markedly upregulated in carcinoma-associated fibroblasts (CAFs) co-cultured with oral squamous cell carcinoma (OSCC) cells; recombinant CCL7 promoted OSCC invasion and migration, and this was inhibited by CCL7 neutralizing antibody or anti-CCR1/anti-CCR3 antibodies, establishing CCL7-CCR1/CCR3 signaling as the axis for CAF-mediated cancer invasion.\",\n      \"method\": \"Microarray of co-culture vs monoculture, qRT-PCR, ELISA, invasion/migration assays, neutralizing antibody treatments, RT-PCR for receptor expression on cancer cells\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional neutralization experiments with specific readout, receptor identification by RT-PCR, single lab\",\n      \"pmids\": [\"19937793\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TLR9 signaling promotes early induction of CCL7 (but not CCL2) in the lung during Cryptococcus neoformans infection; CCL7 reconstitution in TLR9-deficient mice restored CD11b+ dendritic cell accumulation, IFN-γ production, and effector cell recruitment, placing CCL7 downstream of TLR9 in the afferent phase of antifungal immunity.\",\n      \"method\": \"TLR9-KO mice, C. neoformans lung infection, CCL7 reconstitution by intratracheal administration, flow cytometry for immune cell subsets, cytokine ELISA, fungal burden\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (TLR9-KO) combined with cytokine reconstitution, multiple cellular and molecular readouts\",\n      \"pmids\": [\"22422883\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CCL7 has multiple glycosaminoglycan (GAG)-binding epitopes distributed across its surface (identified by hydroxyl radical footprinting and mutagenesis), enabling it to bind heparan sulfate with high affinity (~equivalent to CCL2) as a functional monomer without oligomerization; this is distinct from CCL2, which requires oligomerization for full GAG binding affinity.\",\n      \"method\": \"Hydroxyl radical footprinting (mass spectrometry), site-directed mutagenesis, surface plasmon resonance with heparan sulfate\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal structural and biophysical methods (footprinting, mutagenesis, SPR) in a single rigorous study\",\n      \"pmids\": [\"24727473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Let-7d directly targets the 3'UTR of CCL7 mRNA; let-7d overexpression in renal cell carcinoma cells reduced CCL7 protein, suppressed PBMC recruitment in vitro and tumor macrophage infiltration in vivo; exogenous CCL7 reversed let-7d-mediated inhibition of migration and PBMC recruitment, establishing CCL7 as a direct target of let-7d regulation.\",\n      \"method\": \"Luciferase 3'UTR reporter assay for let-7d targeting, qRT-PCR, cell migration/PBMC recruitment assays, xenograft mouse models, rescue experiments with exogenous CCL7\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct 3'UTR targeting confirmed by luciferase assay, functional rescue experiments, in vivo xenograft model, single lab\",\n      \"pmids\": [\"25193015\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CCL7 in rhinovirus 1B infection drives neutrophil and macrophage influx into lungs and activates NF-κB p65/p50 subunits and airway hyperreactivity; CCL7 neutralization reduced NF-κB activation and airway hyperreactivity in non-allergic mice, linking CCL7 to NF-κB-mediated inflammation downstream of rhinovirus infection.\",\n      \"method\": \"In vivo murine RV1B infection, anti-CCL7 antibody neutralization, NF-κB subunit activation assay, lung function measurement (airway hyperreactivity), flow cytometry for leukocyte influx\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo neutralization with NF-κB pathway readout, single lab, multiple outcome measures\",\n      \"pmids\": [\"25847975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CCL7 signals through CCR3 on colon cancer cells to promote EMT, cellular proliferation, invasion, and migration via ERK and JNK signaling pathways; CCL7-overexpressing HCT116/HT29 cells showed enhanced liver and lung metastasis in orthotopic mouse models.\",\n      \"method\": \"CCL7 overexpression in colon cancer cell lines, in vitro invasion/migration/proliferation assays, ERK/JNK pathway inhibitor experiments, ectopic and orthotopic mouse xenograft models\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo functional studies with pathway inhibitors, single lab\",\n      \"pmids\": [\"27167205\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Intrathecal injection of CCL7 induced dose-dependent pain-related behavior in naive mice; intrathecal neutralizing anti-CCL7 antibody attenuated CCI-induced neuropathic pain and augmented morphine/buprenorphine analgesia; spinal CCL7 is produced by both microglia and astrocytes after sciatic nerve injury, placing CCL7 in the spinal nociceptive signaling axis.\",\n      \"method\": \"Chronic constriction injury (CCI) mouse model, intrathecal CCL7 injection (dose-response), intrathecal anti-CCL7 antibody, von Frey and cold plate pain tests, qRT-PCR for CCL7 in spinal cord, primary glial cell cultures\",\n      \"journal\": \"Cytokine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo gain- and loss-of-function with behavioral readout, cellular source identified in vitro, single lab\",\n      \"pmids\": [\"31003094\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CCL7 directly antagonizes neutrophil migration in vitro and negatively regulates neutrophil recruitment in Leishmania major-infected skin in vivo; CCL7-deficient mice showed enhanced neutrophilic infiltration with elevated IL-17 gene profile, and CCL7 add-back specifically reduced neutrophil influx, revealing a non-redundant role for CCL7 in limiting neutrophilic inflammation.\",\n      \"method\": \"CCL7-KO mice, L. major infection model, in vitro neutrophil migration assay with CCL7, in vivo CCL7 reconstitution, flow cytometry, cytokine profiling, parasite burden\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with in vivo reconstitution and in vitro direct assay; multiple orthogonal readouts; clear mechanistic conclusion\",\n      \"pmids\": [\"30671055\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Irisin promotes C2C12 myoblast proliferation through ERK phosphorylation–dependent upregulation of CCL7; CCL7 knockdown suppressed irisin-induced proliferation, placing CCL7 as a downstream effector of irisin-ERK signaling in myoblast proliferation.\",\n      \"method\": \"Irisin treatment of C2C12 cells, ERK inhibitor (U0126), transcriptomic analysis, qRT-PCR, CCL7 siRNA knockdown, proliferation assays (Pcna, Mki67, Mcm2)\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown establishes functional requirement, pathway inhibitor confirms ERK dependency, single lab\",\n      \"pmids\": [\"31518371\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CCL7 recruits conventional DC1 (cDC1) into the lung tumor microenvironment to promote CD8+ and CD4+ T cell expansion; CCL7-deficient KP mice showed impaired cDC1 infiltration and T cell expansion, and CCL7 administration alone or with anti-PD-1 inhibited tumor development, establishing CCL7 as a cDC1-recruiting chemokine that enhances checkpoint immunotherapy.\",\n      \"method\": \"CCL7-KO in KrasLSL-G12D/Tp53fl/fl (KP) and KrasLSL-G12D/Lkb1fl/fl (KL) mouse models, flow cytometry, intratracheal CCL7 administration, anti-PD-1 combination therapy, survival analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO and reconstitution in syngeneic in vivo model, multiple cellular readouts, replicated across two NSCLC models\",\n      \"pmids\": [\"33257678\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"B lymphocytes (particularly B220low innate B cells) produce CCL7 to recruit neutrophils and monocytes to the injured kidney; CCL7 blockade in mice reduced myeloid cell infiltration and ameliorated acute kidney injury, establishing B cell-derived CCL7 as a driver of sterile innate inflammation in AKI.\",\n      \"method\": \"Mouse AKI model, flow cytometry for B cell subsets and myeloid cells, B cell CCL7 production measurement, Siglec-G-deficient mice (increased innate B cells), in vivo CCL7 antibody blockade, human AKI patient cohort urinary CCL7 levels\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic model (Siglec-G-KO), antibody blockade with cellular quantification, multiple mouse and human cohorts\",\n      \"pmids\": [\"32737150\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SOX18 directly transactivates CCL7 promoter; CCL7 and CCR1 form a positive feedback loop (CCL7-CCR1-ERK/ELK1-SOX18) promoting gastric cancer invasion and metastasis; CCL7/MCAM knockdown reduced SOX18-mediated invasion, and CCR1 inhibitor BX471 suppressed SOX18-mediated metastasis.\",\n      \"method\": \"ChIP assay, luciferase reporter, CCL7/MCAM knockdown and overexpression, invasion/migration assays, ERK/ELK1 pathway inhibition, in vivo mouse metastasis models, BX471 (CCR1 inhibitor) treatment\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct transcriptional activation confirmed, functional rescue/knockdown experiments, defined signaling axis, single lab\",\n      \"pmids\": [\"32616889\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CCL7 and CCL2 redundantly mediate migration of CCR2+/CX3CR1+ immunosuppressive M-MDSCs into the glioblastoma tumor microenvironment via CCR2; combined neutralization of CCL2 and CCL7 completely blocked CCR2-expressing cell migration to glioma-conditioned media, while single knockdown of either was insufficient.\",\n      \"method\": \"Bone marrow-derived MDSC migration assays with recombinant CCL2/CCL7, KR158B glioma CCL2/CCL7 knockdown, CCL2+CCL7 combined neutralization antibody, flow cytometry for tumor-infiltrating MDSCs in vivo\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo combination neutralization establishes redundancy, multiple cell and molecular readouts, single lab\",\n      \"pmids\": [\"36685592\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BRG1 (a chromatin remodeling protein) interacts with AP-1 to drive CCL7 transcription in hepatocytes in a redox-sensitive manner; BRG1 hepatocyte-specific deletion abolished CCL7 induction and macrophage infiltration in liver injury models; CK2-catalyzed phosphorylation of BRG1 mediates this regulation, and the process is blocked by the antioxidant N-acetylcysteine.\",\n      \"method\": \"Hepatocyte-specific BRG1 conditional KO mice, LPS/MCD diet liver injury models, in vitro LPS/palmitate treatment of hepatocytes, Co-IP (BRG1-AP-1 interaction), pharmacological inhibition (N-acetylcysteine), ChIP, macrophage migration assay\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO in vivo, Co-IP for protein interaction, ChIP for chromatin regulation, pharmacological inhibition, multiple orthogonal methods\",\n      \"pmids\": [\"34454163\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CCL7 promotes M1 macrophage polarization via CCR1/JAK2/STAT1 signaling; in vivo CCL7-neutralizing antibody reduced macrophage infiltration and attenuated angiotensin II-induced abdominal aortic aneurysm; JAK2/STAT1 inhibition blocked CCL7-induced M1 activation in macrophages.\",\n      \"method\": \"Ang II mouse AAA model, ex vivo macrophage polarization assays, CCR1 blockade, JAK2/STAT1 inhibitor, in vivo CCL7-neutralizing antibody treatment, histology/immunostaining\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo neutralization and in vitro pathway inhibition, multiple readouts, single lab\",\n      \"pmids\": [\"34189838\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Astrocyte-derived CCL7 promotes microglial activation and pro-inflammatory cytokine release after traumatic brain injury; CCL7 knockout improved microglia-controlled inflammation and neurological outcomes; CCL7-siRNA attenuated LPS-induced pro-inflammatory markers in astrocyte-microglia co-cultures.\",\n      \"method\": \"Rat TBI model, CCL7-KO, in vitro LPS-stimulated astrocyte-microglia co-cultures with CCL7-siRNA, cytokine/marker quantification, neurological scoring\",\n      \"journal\": \"International immunopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo KO with behavioral and molecular readouts, in vitro siRNA confirmation, single lab\",\n      \"pmids\": [\"34293712\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CCL7 impairs endothelial function through CCR3 via downregulation of AKT-eNOS and AKT/NRF2/HO-1/VEGF/SDF-1 pathways and upregulation of ERK/NF-κB/IL-1β/IL-6/TNF-α pathways; CCL7 is induced in endothelial cells by high glucose through c-Fos/c-Jun signaling; endothelial cell-specific Ccl7 knockout in STZ-diabetic mice ameliorated vasculopathy, neovasculogenesis, and wound repair.\",\n      \"method\": \"CCL7 KD/neutralization in endothelial cells, recombinant CCL7 treatment, specific pathway inhibitors (AKT, ERK, NF-κB), Ccl7 global KO and endothelial cell-specific KO mice in STZ/db/db/HFD DM models, tube formation/migration assays, in vivo ischemia/wound models, flow cytometry for circulating EPCs\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models (global KO, EC-specific KO, antibody neutralization), multiple in vitro and in vivo readouts with defined signaling pathways, replicated across multiple DM models\",\n      \"pmids\": [\"39231238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Endothelial cell-derived CCL7 signals via CCR1 on macrophages to upregulate KAT2A expression, which catalyzes STAT1 succinylation; this epigenetic modification increases STAT1 binding to glycolytic gene promoters, driving metabolic reprogramming (enhanced glycolysis) and M1 polarization in macrophages, promoting septic acute lung injury; Ccr1-KO mice showed attenuated lung inflammation.\",\n      \"method\": \"EC-specific CCL7 inhibition in sepsis model, CCR1-KO mice, KAT2A expression analysis, STAT1 succinylation assay, ChIP for STAT1 binding to glycolytic gene promoters, metabolic flux assay, macrophage polarization assay\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined epigenetic mechanism (succinylation) with ChIP, genetic KO model, functional macrophage polarization readout; single lab, abstract-level detail\",\n      \"pmids\": [\"40755420\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CCL7 secreted by Mo-MDSCs binds CCR2 on colorectal cancer micro-metastatic cells and activates JAK/STAT3 pathway to break dormancy and promote metastatic outgrowth; Co-immunoprecipitation confirmed CCL7-CCR2 co-localization; CCL7 inhibition maintained CRC cells in dormancy and reduced metastasis.\",\n      \"method\": \"Co-immunoprecipitation (CCL7-CCR2 interaction), in vitro dormancy cell models, mouse liver metastasis models, flow cytometry for MDSCs, qRT-PCR/Western blot for JAK/STAT3, in vivo CCL7/MDSC inhibitor administration\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP for protein interaction, in vivo dormancy model, JAK/STAT3 pathway validated, single lab\",\n      \"pmids\": [\"33986252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CCL7 regulates invadopodia maturation by promoting MMP-9 targeting to the invadopodia complex via RhoA signaling; dominant-negative RhoA blocked CCL7/CCR3-induced invadopodia maturation and collagen degradation, while constitutively active RhoA rescued maturation in CCL7-silenced cells; ERK and PI3K pathways regulated the initiation (not maturation) stage.\",\n      \"method\": \"CCL7 siRNA in cancer cells, dominant-negative and constitutively active RhoA overexpression, MMP-9 localization by immunofluorescence, invadopodia/collagen degradation assay, ERK/PI3K inhibitors, in vivo metastasis assay\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic rescue experiments with dominant-negative/constitutively active GTPase, functional invadopodia assay, in vivo validation, single lab\",\n      \"pmids\": [\"32217106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MSC-secreted CCL7 activates CCR1 on colorectal cancer cells, which downstream activates CBP/P300 to acetylate KLF5, promoting CXCL5 transcription; TGF-β (also secreted by MSCs) inhibits this process by regulating SMAD4 to suppress KLF5 transcriptional activation.\",\n      \"method\": \"Co-culture of MSCs with CRC cells, CCL7/CCR1 neutralization/inhibition, ChIP for KLF5-CXCL5 promoter binding, CBP/P300 acetylation assay, TGF-β/SMAD4 pathway analysis, in vivo CRC metastasis models\",\n      \"journal\": \"Molecular therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-based transcriptional mechanism, acetylation assay, multiple pathway inhibitions, in vivo model, single lab\",\n      \"pmids\": [\"35283273\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Oncostatin M (OSM) stimulates CCL7 and CCL8 expression in primary human dermal fibroblasts via ERK1/2 and p38 MAPK pathways, with p38 prolonging CCL7 mRNA half-life through inhibition of tristetraprolin; constitutive JAK2/STAT5 activation suppressed CCL1 but NOT CCL7 expression, demonstrating that CCL7 transcription is MAPK-dependent but STAT5-independent in fibroblasts.\",\n      \"method\": \"Primary human dermal fibroblast stimulation with OSM, selective MAPK inhibitors, STAT transcription factor knockdown, tristetraprolin studies, mRNA stability assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pathway inhibitors and STAT knockdowns with quantitative mRNA/protein readouts, single lab\",\n      \"pmids\": [\"18981157\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PAR1 antagonism reduces acute LPS-induced neutrophilic lung inflammation by suppressing CCL2 and CCL7 expression (but not CXCL1/CXCL2 or TNF/IL-6); antibody neutralization of both CCL2 and CCL7 reduced LPS-induced leukocyte and neutrophil accumulation; CCL7 was localized by IHC specifically to pulmonary epithelium; intranasal recombinant CCL7 alone recruited neutrophils to airspaces; lung neutrophils had increased CCR1/CCR2 and decreased CXCR2 compared to circulating neutrophils.\",\n      \"method\": \"Mouse LPS lung inflammation model, PAR1 antagonist treatment, antibody neutralization of CCL2/CCL7, IHC for cellular source, intranasal recombinant CCL7 administration, flow cytometry for chemokine receptor expression on neutrophils\",\n      \"journal\": \"American journal of respiratory cell and molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal in vivo approaches (PAR1 antagonism, combined antibody neutralization, recombinant protein), cellular source identified, receptor switch characterized, replicated across conditions\",\n      \"pmids\": [\"23972264\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CCL7 in psoriatic lesional skin is markedly upregulated compared to other chemokines; keratinocytes and dermal blood endothelial cells are its cellular sources; CCL7 blockade in imiquimod-induced psoriasis-like mouse model reduced myeloid inflammation and key cytokines (CCL20, IL-12p40, IL-17C) and increased IL-4; TNF-α blocker infliximab downregulated CCL7 within 16 hours in human lesional skin, placing CCL7 downstream of TNF-α in Th1/Th17 inflammation.\",\n      \"method\": \"Quantitative RT-PCR in human skin biopsies, imiquimod mouse model with CCL7 blockade, infliximab human clinical sample analysis, cytokine profiling\",\n      \"journal\": \"Experimental dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo antibody blockade with cytokine readouts, human clinical intervention data, cellular source identified, single lab\",\n      \"pmids\": [\"25828150\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CCL7 (MCP-3) is a CC chemokine that functions as a chemotactic factor for monocytes, neutrophils, eosinophils, NK cells, and T lymphocytes by binding multiple chemokine receptors (CCR1, CCR2, CCR3, CCR5, CCR10), with receptor promiscuity enabled by its monomeric structure and distributed GAG-binding epitopes; it acts downstream of TLR9, PAR1, and redox/NFκB/MAPK signaling to orchestrate innate and adaptive immune cell trafficking, can act as a natural CCR5 antagonist, promotes cancer invasion via CCR3-RhoA-MMP-9 and CCR1-JAK/STAT3 axes, drives M1 macrophage polarization through CCR1/JAK2/STAT1 succinylation, and regulates tissue homeostasis including dopamine neuron differentiation, endothelial function via the AKT-eNOS pathway, and ER stress responses indirectly through cellular context.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CCL7 (MCP-3) is a secreted CC chemokine that orchestrates leukocyte trafficking during innate and adaptive immune responses by engaging multiple CC chemokine receptors [#0, #3, #6]. Originally cloned as a monocyte chemoattractant [#0], it binds CCR1 [#2], CCR2 [#4], and CCR5 [#8] with high affinity, and its broad receptor promiscuity—encompassing monocytes, T lymphocytes, eosinophils, and neutrophils—rests on a monomeric architecture bearing GAG-binding epitopes distributed across its surface, allowing high-affinity heparan sulfate binding without oligomerization, distinct from CCL2 [#18]. Its N-terminus is dispensable for receptor binding but essential for receptor activation, such that N-terminally truncated CCL7 becomes a multi-receptor antagonist [#5]; at CCR5 the intact chemokine itself behaves as a natural antagonist, binding without triggering signaling or internalization [#8]. In vivo, epithelial- and endothelial-derived CCL7 is a non-redundant driver of eosinophil and neutrophil recruitment in allergic, oxidative, and infectious airway inflammation [#7, #9, #10, #38], while contributing additively with CCL2 to CCR2-dependent inflammatory monocyte egress and Th2 restraint during fungal and bacterial infection [#11, #15], and acting downstream of TLR9 in antifungal immunity [#17]. Beyond chemotaxis, CCL7 can negatively regulate neutrophilic inflammation [#23] and recruits cDC1 to promote antitumor T cell responses [#25]. In cancer, CCL7 promotes invasion and metastasis through CCR3-RhoA-MMP-9-dependent invadopodia maturation [#35], CCR1-driven transcriptional feedback and acetylation cascades [#27, #36], and CCR2-JAK/STAT3 signaling that breaks micrometastatic dormancy [#34]. CCL7 also drives macrophage M1 polarization via CCR1/JAK2/STAT1 [#30] and via a CCR1-KAT2A-STAT1 succinylation axis linking it to glycolytic reprogramming in lung injury [#33], and impairs endothelial function through CCR3 by suppressing AKT-eNOS signaling [#32]. Its expression is induced by inflammatory cytokines through NF\\u03baB and p38/JNK MAPK pathways [#14, #37] and by redox-sensitive BRG1-AP-1 chromatin remodeling [#29], and is post-transcriptionally controlled by let-7d [#19].\"\n  ,\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Establishing CCL7's molecular identity and core activity answered whether it was a distinct chemoattractant, defining it as a CC chemokine that recruits monocytes and is regulated by inflammatory stimuli.\",\n      \"evidence\": \"cDNA cloning, recombinant expression, chemotaxis and glycosylation analysis, mRNA regulation studies in U937/PBMC\",\n      \"pmids\": [\"8318676\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptors mediating monocyte chemotaxis not yet identified\", \"Neutrophil activity initially absent, later found context-dependent\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Identifying the murine orthologue (MARC/FIC) enabled in vivo genetic and infection studies of CCL7 function.\",\n      \"evidence\": \"cDNA library screening from LPS-stimulated WEHI-3 macrophages with human MCP-3 probe and sequencing\",\n      \"pmids\": [\"8002978\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional conservation with human CCL7 not directly tested at this stage\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Defining the receptor repertoire answered how a single chemokine recruits diverse leukocytes, showing CCL7 binds CCR1 and shares receptor sites with MIP-1\\u03b1/RANTES/MCP-1 while engaging unique sites.\",\n      \"evidence\": \"CCR1 transfection with radioligand binding and migration assays; primary monocyte/neutrophil binding and cross-desensitization\",\n      \"pmids\": [\"7545673\", \"7589134\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full receptor set not enumerated\", \"Structural basis of promiscuity not yet defined\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Receptor mapping and structure-activity dissection established CCR2 as a murine receptor and showed the N-terminus controls activation versus binding, yielding a multi-receptor antagonist.\",\n      \"evidence\": \"mCCR2 cloning and radioligand competition; MCP-3(10-76) truncation with binding, chemotaxis and enzyme release assays; leukocyte cross-competition\",\n      \"pmids\": [\"8662823\", \"8631850\", \"8642349\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous proteolytic generation of truncated antagonist not demonstrated in vivo\", \"Receptor mediating eosinophil recruitment defined only by shared competition\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Characterizing CCR5 engagement revealed that CCL7 can act as a natural receptor antagonist, binding without signaling and blocking agonist responses.\",\n      \"evidence\": \"Radioligand competition, calcium flux, chemotaxis, internalization and HIV infection assays in CCR5 transfectants\",\n      \"pmids\": [\"10477718\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological relevance of CCR5 antagonism in vivo not established\", \"Weak HIV-inhibitory activity not therapeutically pursued here\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"In vivo neutralization studies established CCL7 as a non-redundant driver of both eosinophil and neutrophil recruitment in airway inflammation, identifying epithelium and endothelium as sources.\",\n      \"evidence\": \"Mouse OVA, ozone and schistosomal granuloma models with anti-CCL7 neutralization, IHC source localization, IL-4 regulation in cultured endothelium\",\n      \"pmids\": [\"9144514\", \"11777981\", \"12107110\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor used on recruited neutrophils not resolved at this stage\", \"Relative contribution of epithelial vs endothelial source unclear\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Genetic knockout and pathway studies defined CCL7's tissue-homeostatic and regulatory roles beyond inflammation, including additive monocyte recruitment with CCL2, dopamine neuron differentiation, and fibroblast collagen production.\",\n      \"evidence\": \"CCL7-KO Listeria model with monocyte flow cytometry; ventral midbrain precursor cultures with Nurr1-KO; fibroblast collagen/TGF\\u03b2 and OSM-MAPK studies\",\n      \"pmids\": [\"18453605\", \"18420193\", \"19038247\", \"18981157\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single-knockout phenotypes incompletely recapitulate CCR2 loss, indicating redundancy\", \"Direct receptor on dopaminergic precursors inferred from expression\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defining cytokine-driven induction pathways established how CCL7 expression is controlled in glia and during fungal infection, and confirmed functional redundancy with CCL2 via CCR2 in suppressing Th2 responses.\",\n      \"evidence\": \"Rat astrocyte cultures with NF\\u03baB/MAPK inhibitors; CCL2-KO/CCR2-KO mice with CCL7 neutralization and IL-4 readouts in Histoplasma infection\",\n      \"pmids\": [\"19577550\", \"19587014\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Astrocyte signaling defined pharmacologically, not genetically\", \"Mechanism by which CCR2 limits IL-4 not fully resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Biophysical and post-transcriptional studies answered how CCL7 achieves receptor promiscuity and GAG binding as a monomer and how its abundance is fine-tuned, identifying distributed GAG epitopes and let-7d regulation.\",\n      \"evidence\": \"Hydroxyl radical footprinting, mutagenesis and SPR with heparan sulfate; luciferase 3'UTR reporter and rescue assays for let-7d in RCC\",\n      \"pmids\": [\"24727473\", \"25193015\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo consequence of GAG-binding mutations not tested\", \"let-7d regulation shown in one tumor context\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Cancer studies established CCL7 as a stromal- and tumor-derived driver of invasion and metastasis through defined receptor-effector axes (CCR1/CCR3) and MAPK signaling.\",\n      \"evidence\": \"CAF/OSCC co-culture with CCR1/CCR3 neutralization; CCL7 overexpression in colon cancer with ERK/JNK inhibitors and xenografts; psoriasis source/blockade studies\",\n      \"pmids\": [\"19937793\", \"27167205\", \"25828150\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor usage varies across tumor types without unifying model\", \"Single-lab xenograft systems\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Genetic and mechanistic studies resolved divergent context-dependent roles—antitumor cDC1 recruitment, neutrophil suppression, pro-tumor RhoA-MMP-9 invadopodia maturation, dormancy escape, and sterile injury inflammation.\",\n      \"evidence\": \"CCL7-KO KP/KL lung tumor and reconstitution; CCL7-KO Leishmania model with add-back; RhoA dominant-negative/CA rescue invadopodia assays; CCR2-Co-IP dormancy model; B cell-derived CCL7 AKI model; PAR1/MDSC studies\",\n      \"pmids\": [\"33257678\", \"30671055\", \"32217106\", \"33986252\", \"32737150\", \"23972264\", \"36685592\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants selecting pro- vs anti-inflammatory/tumor outcome not defined\", \"Receptor-specific signaling bifurcations incompletely mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Mechanistic dissection linked CCL7 to macrophage polarization, chromatin-level transcriptional control, and glial neuroinflammation, broadening its role to metabolic and epigenetic reprogramming.\",\n      \"evidence\": \"CCR1/JAK2/STAT1 macrophage M1 studies in AAA; hepatocyte BRG1-AP-1 redox-sensitive transcription with Co-IP/ChIP; astrocyte-microglia CCL7 in TBI\",\n      \"pmids\": [\"34189838\", \"34454163\", \"34293712\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"BRG1-AP-1 axis shown in liver only\", \"Glial source mechanisms largely correlative\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Endothelial-focused genetic studies established CCL7 as a regulator of vascular function and macrophage metabolic reprogramming via CCR3 and CCR1 signaling.\",\n      \"evidence\": \"EC-specific and global Ccl7 KO in diabetic models with AKT-eNOS pathway analysis; sepsis model with CCR1-KO, KAT2A/STAT1 succinylation and ChIP-based glycolytic gene readouts\",\n      \"pmids\": [\"39231238\", \"40755420\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Succinylation mechanism reported at abstract-level detail\", \"Translation of endothelial CCL7 axis to human disease not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The molecular determinants that switch CCL7 between agonist and antagonist behavior at shared receptors, and between pro- and anti-inflammatory or pro- and antitumor outcomes in different tissues, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model linking receptor choice to functional outcome\", \"Structural basis of biased signaling not defined\", \"In vivo relevance of natural antagonism untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [2, 3, 6, 21, 25]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 7, 9, 38]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [7, 11, 17, 25]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [2, 3, 6]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 4, 8, 30, 32]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [21, 27, 34, 35]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CCR1\", \"CCR2\", \"CCR3\", \"CCR5\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":8,"faith_total":8,"faith_pct":100.0}}